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Abstract: 
Introduction and Background 
Hepatitis B virus (HBV) is one of the important aetiologies for the development of 
hepatocellular carcinoma (HCC). Hepatitis B virus X protein (HBx) is believed to be 
critical in the carcinogenesis of HCC. HBx is a multifunctional protein of 154 amino 
acids. It possesses the repression domain at the N-terminal and two transactivating 
domain at the C-terminal. The mechanism of HBx involved in the carcinogenesis of 
HCC is not fully understood. It can transactivate transcriptions, activate signal 
transduction cascades and affect viral replication. HBx is also thought to affect 
oxidative status, antioxidant levels and apoptosis in liver cells. High antioxidant levels 
may cause drug resistance in chemotherapy. 
Objectives 
In this project, the effects of HBx on the oxidative state/antioxidant level and apoptosis 
in hepatic cell lines are investigated. The specific domain(s) which is/are responsible for 
the changes are also studied. 
Methods 
Wild type full length HBx and 6 HBx deletion/insertion mutants were constructed and 
the plasmids were stably transfected into Chang Liver (CL) cell lines. The constructed 
cell lines included CL_50 (a.a.1-50), CL一51 (a.a 51-154), CL一68 (Arg-Pro insertion at 
a.a. 68)，CL一88 (Arg-Pro insertion at a.a. 88)，CL_106 (a.a. 106-154), CL一 136 (a.a. 1-
136) and CL_x (full length HBx). The antioxidant level, as reflected by the level of 
glutathione (GSH) and superoxide dismutase (SOD), was measured. The expressions of 
several proteins including inhibitor of apoptosis (cIAP-2) and Bcl-2 which are involved 
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in the apoptotic pathway were assessed by Western blot. As many of the chemotherapy 
drugs kill tumor cells via generating free radicals, high antioxidant level in cells may 
lead to drug resistance in cancer cell. MTT cell proliferation assay was performed to 
test the proliferation rate and the effect of cell killing by different cytotoxic drugs, 
including fluorouracil (5FU) and doxorubicin (DOX). 
Results 
Cells that were transfected by full-length HBx (CL_x) expression have the highest GSH 
level than the negative control (CL). Mutants CL_51 and CL_106 also showed a higher 
GSH level than the negative control. But there was not much difference in SOD between 
different cell lines. CL_x transfected cells which had the higher major antioxidant GSH 
was less susceptible to chemotherapeutic drugs killing than the non-transfected control 
in the MTT cell proliferation assay. Furthermore, the C-terminal of HBx was found to 
be responsible for apoptosis in hepatic cells. 
The mechanism how HBx affects apoptosis is still unclear. We attempted to determine 
the specific domain of HBx protein which is responsible for the apoptotic effect. Also, 
the expression of anti-apoptotic protein Bcl-2 and cIAP-2 was found to be elevated in 
CL_51 and CL_68 during transient transfection. The domain responsible for apoptosis 
(in response to chemotherapeutic drugs) is still under investigation. 
Conclusion 
HBx is involved in hepatocellular carcinoma development. The GSH level in hepatic 
cells is affected probably by the C-terminal of HBx and high GSH level may cause drug 
resistance. The C-terminal of HBx would also affect the apoptotic rate and cIAP2 and 
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Chapter 1: Introduction 
1.1 Epidemiology of Hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is a leading cause of cancer death 
worldwide. By 2002, the number of new cases if HCC was over 700,000 and 
the mortality rate ranked fourth among cancer (World Health Report, 2003). 
The incidence rates are much higher in Southeast Asia and Sub-Saharan 
Africa than that in North America, Western Europe and Australia (Bruix et al, 
2004). There is also a male predominance HCC incidence, with over 
500,000 and 200,000 new cases in males and females in 2002 respectively 
(World Health Report, 2003). The difference in incidence rate among gender 
and geographic area maybe due to genetic and physiological differences, and 
also the prevalence of variable risk factors (Guerreo and Roberts, 2005). The 
mortality from HCC is almost equivalent to the incidence figures in the same 
year. It ranked fourth in mortality due to cancer behind lung, stomach and 
colon cancer (Seeff and Hoofhagle, 2006). 
1.2 Etiology of Heptocellular carcinoma (HCC) 
The risk factors of developing HCC include hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infection (Idilman et al, 1998)，exposure to alfatoxin 
B1 (Sun et al, 1999), excessive alcohol consumption, drugs and chemicals, 
and cirrhosis (Niederau et al, 1985). Other risk factors include obesity and 
diabetes (Regimbeau et al, 2004) and hypothyroidism (Reddy et al, 2007). 
However, the cause of HCC in many patients is unknown. 
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1.3 HBV genome structure 
Chronic HBV infection is one of the most important risk factors for HCC 
development (Guerrero and Roberts, 2005). Hepatitis B virus (HBV) is a 
member of the hepadnavirus family. Human HBV induces acute and chronic 
hepatitis. It is an enveloped virus with a small approximately 3.2kb circular 
genomic DNA which is partially double-stranded with a single-stranded gap 
region (Guerrero and Roberts, 2005). There are four overlapping opening 
reading frames (ORFs) that encode the viral proteins and the cw-elements 
that are required for regulation of HBV gene expression and replication. The 
four HBV ORFs include the precore/core (C)，surface (S)，polymerase (P) 
and HBx (X) encoding regions (Arbuthnot et al, 2000) (Figure 1.1). 
HBV was divided into nine serological types: adw2, adw4, adr, adrq-, aywl, 
ayw2, ayw3, ayw4 and ayr (Courouce-Pauty et al, 1983) according to a single 
amino acid change at positions 122 {d orjv) and 160 (r or w) in the S protein 
(Okamoto et al，1988). Also, it was divided into seven genotypes, A to G 
according to genetic divergence in complete genome sequences (Norder et al, 
1993，1994; Magnius and Norder, 1995; Stuyver et al’ 2000). 
1.4 HBV pathogenesis 
HBV infection causes both acute and chronic hepatitis. Chronic hepatitis 
develops in patients who cannot eliminate the virus after initial infection. 
After entering the host cell, the HBV DNA genome is relocated to the cell's 
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nucleus and converted to covalent closed circular DNA (cccDNA). Then the 
HBV 3.5kb pregenomic RNA intermediate from the cccDNA viral 
minichromosome was transcribed by host cell RNA polymerase II. The 
RNA template generated is reversely transcribed in the nucleocapsid and the 
nucleocapsids then proceed to the Golgi for coating of surface antigen 
envelope proteins. Finally, the viral particles are released out of the host cell 
(Lee and Locamini, 2004) (Figure 1.2). 
HBV integrations into the host genome occur in about 85 to 90% HBV-
related HCC. Integrations can be either a single or multiple integrations 
causing genetic alterations within the host genome such as deletions, 
translocations, production of fusion transcripts, and finally lead to genomic 
instability. The process usually gives growth advantage to the host cells by 
promoting cell proliferation and suppressing apoptosis (Idilman et al, 1998; 
Robinson, 1994). The pattern of integration is distinct and is usually featured 
by enhanced DNA replication and DNA damage during chronic 
inflammation as the availability of DNA ends in host genomic DNA is 
increased during cycles of cell death and regeneration (Bill and Summers, 
2004). HBx integrations often occur in HBV-induced HCC with C-terminal 
deleted (Wang et al, 2004). These deletions lose their capacity for apoptosis 
and cell cycle arrest which in turn lead to unregulated cell proliferation (Tu et 
al, 2001). 
1.5 Hepatitis B virus X protein (HBx) 
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HBx is thought to be a critical protein for the carcinogenesis of 
hepatocellular carcinoma (HCC). It is reported to be required for natural 
infection in woodchuck and replication in other mammals (Chen et al, 1993; 
Zoulim et al, 1994). It did not show homology to any know protein and is a 
multifunctional regulatory protein of 154 amino acids with 17 kDa in 
molecular weight. The N-terminal one-third (a.a 1-50) is believed to be the 
regulatory domain, and the transactivation domain is at the C-terminal (a.a. 
51-154). It has been reported that HBx contains two Kunitz-type serine 
protease inhibitors at region a.a. 61 to 69 and 132 to 139 which is important 
for its transcriptional activity and apoptosis (Takada et al, 1994). Regions 
between a.a. 52 to 65 and 88 to 154 were important for HBx function in HBV 
replication (Tang et al, 2005). Regions between a.a. 102 to 136 and 111 to 
154 were reported to bind p53 (Elmore et al, 1997; Lin et al, 1997). Region 
between a.a. 84 to 114 was reported to be the target domain to proteosome 
(Stohwasser et al, 2003) (Figure 1.3). 
The X-ORF is conserved in mammalian hepadnaviruses and is located 
downstream to Enhl. It is partially overlapped with the P ORF at the N-
terminal, and several cis-element of the PreC-C promoter at the C-terminal 
(Tang etal, 2006). 
The subcellular localization of HBx is mainly in the cytoplasm and 
perinuclear of hepatocytes of infected liver (Su et al，1998; Sirma et al, 1998; 
Jin et al, 1990; Zentgraf et al, 1990; Haruna et al, 1991). Small amount of 
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the protein is reported to be located in nucleus when HBx is ecotropically 
expressed in cells (Nomura et al, 1999; Dandri et al’ 1998). Two groups 
have even reported that HBx is found to be located in the mitochondria 
(Takada et al, 1999; Rahmani et al, 2000). 
1.6 Oxidative stress and antioxidant 
Oxidative stress in cells is caused when there is an imbalance between 
oxidant generation and antioxidant protection. Cells are damaged by reactive 
oxidative species (ROS). ROS are free radicals, reactive anions containing 
oxygen atoms, or molecules containing oxygen atoms that can produce free 
radicals or are chemically activated by them, for example, hydrogen peroxide, 
superoxide, singlet oxygen and peroxynitrite. Oxidative stress can cause 
many diseases including neurodegenerative disease such as Alzheimer's 
disease and Parkinson's disease, cardiovascular disease, cancer and aging 
(Martindale and Holbrook, 2002). 
1.6.1 Glutathione (GSH) 
Glutathione is a low molecular weight sulfur containing tri-peptide consisting 
of glutamate, cysteine and glycine (Figure 1.4). It can be oxidized and can be 
regenerated quickly (Jefferies et al, 2003; Estrela et al, 2006). It functions as 
the main intracellular antioxidant to scavenge free radicals. The diverse 
functions of GSH can be divided into three groups. First, it, together with 
superoxide dismutase (SOD), serves as the main intracellular antioxidant. 
Second, it modulates cell proliferation and immune response. Third, it can 
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regulate signal transduction pathways through N F - K B and protein tyrosine 
phosphatase (Jefferies et al, 2003). 
Glutathione exists in both reduced (GSH) and oxidized (GSSG) form. It is 
mainly synthesized de novo within the liver before releasing into the blood 
stream (Flagg et al, 1994; lantomasi et al, 1997). It can degrade reactive 
oxygen species (ROS) and nitrogen species (RNS) generated during 
metabolism by a redox buffer system (Hayes and McLellen，1999; Berlett 
and Stadtman, 1997). The working mechanism of glutathione redox buffer 
system involves the action of glutathione peroxidases (GPx) which reduce 
ROS and RNS while GSH is oxidized to GSSG. In reverse, the redox status 
inside the cells is maintained by GSH reductase (GRx) by catalyzing the 
formation of two GSH molecules from one molecule of GSSG (Jefferies et al, 
2003) (Figure 1.5). 
GSH has been proven to play a role in ischemia-reperfusion injury, sepsis, 
inflammatory bowel disease and oncology (Jefferies et al, 2003). The level 
of GSH usually reflects the oxidative stress in the cells. In cancer, although 
GSH can inactivate some carcinogens and protect the cells from DNA 
damage by free radicals (Jakobisiak et al, 2003; Sies, 1999)，high level of 
GSH has been found to be associated with mutlidrug resistance in 
chemotherapy and resistance in radiotherapy (Estrela et al, 1995; Meister 
1991; Arrick and Nathan, 1984). 
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1.6.2 Superoxide dismutase (SOD) 
SOD catalyzes the dismutation of superoxide into oxygen (O2) and hydrogen 
peroxide (H2O2). It is an important antioxidant to protect the cells from 
damage by superoxide generated. In eukaryotes, there are generally two 
types of SOD, copper and zinc SOD (Cu/ZnSOD) and manganese SOD 
(MnSOD). Cu/Zn SOD is mainly present in the cytoplasm while MnSOD is 
mainly present in the mitochondria (Oberley and Buettner, 1979). 
Superoxide is one of the main ROS inside cells and it is dismutased into O2 
and H2O2 by SOD. The reaction can be summarized in the two following 
equations: 
M(n+i片-SOD + O2" — Mn+ - SOD + O2 
Mn+ — SOD + O2一 + 2H+ M(n+i)+ - SOD + H2O2. 
where M = Cu (n=l) ； Mn (n=2) ； Fe (n=2) ； Ni (n=2). 
Mutation or deficiency in SOD may lead to different diseases. It has been 
reported that lacking of Cu/ZnSOD may lead to oxidative damage and HCC 
(Elchuri et al, 2005). Also, there is strong evidence that MnSOD is 
antiproliferative in malignant cells (Oberley and Oberley, 1997). However, 
there are also reports that MnSOD overexpression prevents apoptosis (Manna 
eta!, 1998; Fujimura et al, 1999). 
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1.6.3 Oxidative stress in HBV-related liver disease and HCC 
HBV infection has been reported to increase oxidative stress in liver cells in 
many studies (Swietek and Juszczyk, 1997; Chrobot et al, 2000; Demirdag et 
al, 2003; Tanyalcin et al, 2000). High ROS often leads to hepatocyte lesion, 
hepatic fibrosis (Poli，2000) and neoplastic transfromation (Sun et ai, 1989; 
Hagen et al’ 1994). Also, oxidative stress caused by chronic viral infection 
will lead to DNA damage and fragmentation (Bolukbas et al, 2005; Hagen et 
al, 1994; Higuchi, 2004). In addition, HBx has been reported to affect 
mitochondrial physiology and metabolism in hepatic cells, and leads to the 
generation of ROS which activate a series of transcription factors (Waris et al, 
2001). All these events will lead to the development of HCC. 
The antioxidant levels and oxidative stress index in chronic HBV infection 
and HCC have been reported by different groups. Among them, the level of 
catalase (CAT) and SOD was reported to be decreased in children with 
chronic hepatitis but the level of glutathione peroxidase (GPx) was found to 
be increased (Chrobot et al, 2000). Also, the expression of both Cu/ZnSOD 
and MnSOD has been reported to be decreased by 80-90% in Hep3B cell line 
which contains the HBV genome (Ohhira et cd, 1995). Moreover, the total 
peroxide level and oxidative stress index was found to be higher in cirrhotic 
and hepatitis B positive patients (Bolukbas et al, 2005). The expression 
levels of antioxidant enzymes, CAT and glutathione reductase (GRx), were 
found to be increased in well-differentiated HCC cell lines (Yang et al, 2005). 
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1.7 Apoptosis and necrosis 
There are two different processes of cell deaths: apoptosis and necrosis. 
Apoptosis is a form of programmed cell death which is important for 
elimination of redundant, damaged and viral infected cells (Booy et al, 2005; 
Ferri and Kroemer 2001; Hashemi and Kroczak, 2005). Necrosis is a form of 
traumatic cell death that results from acute cellular injuries. In a cell, 
apoptosis and necrosis may occur independently or they may occur at the 
same time (Johar et al’ 2004). 
Apoptosis is ATP-dependent and does not stimulate immune response 
(Lauber et al, 2004). It is characterized by DNA condensation and 
fragmentation, plasma membrane blebbing, and cell shrinkage. In the end, 
the cell breaks into small membrane-surrounded fragments that are cleared 
by macrophages and neighbour cells (Philchenkov et al, 2004; Reed, 2000). 
In contrast, necrosis results from metabolic disruption and energy depletion, 
mitochondrial and cellular swelling, and activation of enzymes that degrade 
cellular structures. As a result, the cell is lysed and its content is released 
into the surrounding environment. So, necrosis causes inflammation because 
of immune system effector cell recruitment (Ghavami et al, 2005). 
1.7.1 Apoptotic pathways 
Apoptosis can be triggered by wide variety of insults. These include 
deregulation of cellular metabolic pathways (Fisher, 2001), cytokines 
(Thorbum, 2007; Wang and El-Deiry, 2003)，viruses (Huang et al, 2007; 
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Liang et al, 2007) and anticancer drugs (Los et al, 2003). Apoptosis is 
divided into two phases, initiation and execution phase. In the initiation 
phase, apoptosis can be triggered by the intrinsic pathway or the extrinsic 
pathway. 
The intrinsic pathway causes the disruption and permeabilization of the 
mitochondrial membrane and the pro-apoptotic mitochondrial proteins such 
as cytochrome c，Smac/DIABLO, HtrA2 were released. The cytochrome c 
released then activates caspase 9 and initiates the apoptotic caspase cascade. 
On the other hand, Smac/DIABLO and HtrA2 bind and antagonize the 
inhibitor of apoptotic proteins (lAPs) (Wang, 2001; Suzuki et al, 2001). The 
mitochondrial membrane permeabilization is promoted or inhibited by Bcl-2 
family proteins (Kroemer, 2003) (Figure 1.6). 
The extrinsic pathway is initiated by the ligation of transmembrane death 
receptors such as CD95, TNF receptor and TRAIL receptor. The membrane-
proximal (activator) caspases (caspase 8 and caspase 10) are activated and 
they then cleave and activate the effector caspase such as caspase 3 and 
caspase 7. This pathway is regulated by c-FLIP which inhibits the upstream 
activator caspases and lAPs (Reed, 2000; Los et al, 1995) (Figure 1.7). 
1.8 Role of HBx in apoptosis 
It has been reported that apoptotic cell death plays a role in many liver 
diseases including both the acute and chronic ones (Kasahara et al, 2000; 
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Gujral et al’ 2003). The HBx protein is believed to be the most critical 
protein involved in apoptosis and causes HCC. But the role of HBx plays in 
HCC is ambiguous. It has been shown to have both inhibitory and 
stimulatory effect on apoptosis. 
For the apoptotic role, it has been reported that HBx inhibits the antiapoptotic 
protein Bcl-xL (Miao et al, 2005), interacts with c-FLIP and enhances death 
inducing signal (Kim and Seong, 2003)，activates caspase 3 (Kim et al, 2005; 
Terradillos et al, 2002), abrogates the ability of oncogene (Kim et al, 1998), 
activates apoptotic pathway such as MEKK 1/JNK stress-mediate (Doria et al, 
1995; Benn et al，1996; Su and Schneider, 1996) and FasL signaling pathway 
(Shin et al, 1999; Yoo and Lee, 2004). Also, HBx has been reported to be 
involved in p53-independent apoptotic mechanism (Terradillos et al, 1998) 
and subjected to TNF-a killing (Su and Schneider 1997; Kim et al, 2005). 
On the other hand, HBx has been reported to be involved in the antiapoptotic 
pathway. It inhibits p53-mediated apoptosis (Wang et al, 1995; Elmore et al, 
1997; Chung et al, 2003) and disrupts p53 function (Hsieh et al, 2003; Lee 
and Rho, 2000; Feitelson et al, 1993). It also inhibits other apoptotic 
molecules such as caspase 3 (Gottlob et al, 1998)， activates 
phosphatidylinpsitol 3-kinase pathway (Lee et al, 2001; Shih et al, 2000), c-
Jim N-terminal kinase (JNK) pathway (Diao et al, 2001). Besides, HBx can 
promote cell proliferation by activating the Ras-Raf mitogen (MAPK) signal 
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transduction pathway (Cross et al, 1993; Benn and Schneider, 1994; Natoli et 
ah 1994). 
1.9 Transcriptional activity by HBx 
HBx has been shown to have transactivation function in viral life cycle and it 
also transactivates other cellular genes. The C-terminal (a.a. 50-70 and 110-
140) of HBx are thought to be important for transactivation (Koike et al, 
1989; Caselmann et al, 1990). But the mechanism of transactivation is still 
unclear. It is generally believed that HBx activates a wide variety of cellular 
and viral genes in trans such as the HBV enhancers, HIV long-terminal 
repeats, proto-oncogenes c-jun, c-fos and c-myc (Yen, 1996). HBx does not 
bind DNA directly and it stimulates transcription presumably by interacting 
with cellular proteins, nuclear transcription factors and components of signal 
transduction pathways (Sirma et al, 1999). 
The signal transduction pathways activated by HBx include mitogen 
activated protein kinase (MAPK) (Kekule et al, 1993; Luber et al, 1993; 
Benn and Schneider, 1994; Benn et al, 1996)，protein kinase C (PKC) 
(Kekule et al, 1993), Janus family tyrosine kinase (JAK) and signal 
transducer and activators of transcription pathways (STAT) (Lee and Yun, 
1998). 
HBx binds to different transcription factors such as RPB5 of RNA 
polymerasese (Cheong et al，1995), TATA-binding protein (Quadri et al, 
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1995) and CREB (Maguire et al, 1991; Williams and Andrisani, 1995). Also， 
HBx can increase the DNA binding ability and activation of nuclear 
transcription factors N F - K B and A P - 1 (Lucito and Schneider, 1992; Cross et 
al, 1993; Benn and Schneider, 1994; Natoli et al, 1994; Su and Schneider, 
1996). 
1.10 Chemotherapy drug resistance 
Chemotherapy is one of the most common ways of treating cancers besides 
surgical operation and radiotherapy. It has been successful for treating 
testicular cancer and leukemia (Johnstone et al, 2002). However, the effect is 
not so promising for treating epithelial cancers like breast, colon, lung and 
especially liver (Johnstone et al, 2002). The problem of drug resistance is 
not well understood and is thought to be caused by inhibiting the drug-target 
interaction. Also, the overexpression of P-glycoprotein and intracellular 
antioxidant such as the glutathione are believed to be the causes (Johnstone et 
al, 2000; Volm, 1998). So，it has been suggested that the use of antioxidants 
during chemotherapy and radiotherapy should be avoided (D’ Andrea, 2005). 
The mechanism of drug resistance can be summarized in Figure 1.8 
(Johnstone et al，2002). Drug resistance can arise in two levels. Classical 
drug resistance arises when the effect of drugs is inhibited at the drug-target 
interaction stage. The other arises from the effector defects which inhibit the 
downstream cell death signaling pathway (Lowe and Lin, 2000). 
13 
1.11 Objectives of study 
The poor prognosis and drug resistance in liver cancer has made treating 
HCC complicated. In Hong Kong, about 85-90% cases of HCC are HBV-
related and the HBx gene is found to be integrated into the host DNA and it 
is mostly truncated in the HCC samples. HBx is thought to be a critical 
protein in hepatocarcinogenesis and has been reported to have both pro-
apoptotic and anti-apoptotic effect in HCC. Also, HBx has been reported to 
be involved in various apoptotic pathways. 
In this project, wild type HBx gene and six various mutants of HBx are 
transfected into Chang Liver (CL) cell line to evaluate the effect of different 
domains of HBx on the i) antioxidant levels, ii) the apoptotic effects in 
hepatic cells, and iii) the cytotoxicity of the drugs fluorouracil (5FU) and 
doxorubicin (DOX). Also, the pathway in which HBx is involved in 
apoptosis is studied. Hopefully, the HBx domain(s) which is/are responsible 
for apoptosis and how it is related to drug resistance could be found out. 
Thus, the survival rate can be improved. 
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Figure 1.1 Genomic map of HBV showing the 4 open reading frames (ORFs), 
Precore/core (Pre-C/C), Pre-S/ Surface (S), Polymerase (P) and HBx (X). 
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Figure 1.2 Life cycle of HBV. 
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Figure 1.3 Schematic presentation of HBx protein. Regulatory domain (a.a. 1-50), 
transactivation domain (a.a. 51-154), Kunitz domains (a.a 61-69, 132-139), 
regions important for HBV replication (a.a. 52-65，88-154), region binding 
p53 (a.a 102-136, 111-154), region targeting proteasome (a.a 84-114). 
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Figure 1.4 Structure of glutathione (GSH). It is a tripeptide molecule made up of 
glutamate, cysteine and glycine. 
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Figure 1.5 Metabolism of glutathione. Free radicals are reduced by GSH and GSSG is 
formed. Lipid hydroperoxides are also reduced to its corresponding alcohol 
in presence of glutathione peroxidase (GPx). GSSG is reduced back to GSH 
by glutathione reductase (GR) in couple reaction of NADPH to NADP+ 
• (Dringen et al, 2000). 
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Figure 1.6 A schematic diagram showing the intrinsic apoptotic pathway. 
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Figure 1.8 Mechanism of drug action. Classical drug resistance is caused by inhibiting 
the primary effect of drug-target interactions. Drug resistance arising from 
effector defects is caused by mutations in the downstream events and can 
produce multidrug resistance. 
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Chapter Two: Methods and Materials 
2.1 Construction of plasmid 
2.1.1 PCR amplification of wild-type and mutant HBx 
Wild-type full length HBx gene {HBx) and mutants encoding a.a.1-50 
{HBx_50\ a.a.51-154 {HBx_51\ a.a. 106-154 {HBxJ06), a.a.1-136 
(HBx 136), were amplified from full-length HBx plasmid (genotype: B, 
subtype: adw accession no: DQ448619, 1374-1878) obtained from our 
own lab. The two insertion mutants Arg-pro insertion at a.a.68 {HBx_68) 
and a.a.88 {HBx_88\ were amplified from HBx plasmids with site-
directed mutagenesis at the respective positions. The sites of primers for 
amplification of different HBx fragments were shown in Figure 2.1. An 
EcoRl restriction site was located at all forward primers and a Notl 
restriction site was located at the reverse primers. The sequences of the 
primers for amplifying the different fragments of HBx gene, and their 
respective sizes were listed as follows: 
HBx: IJEcoRlJ: 5'-CCG AAT TCA ACC ATG GCT GCT AGG CTG 
TGC-3'; 154一胸I_R: 5'-GAA TGC GGC CGC ATT AGG CAG AGG 
TGA AAA AGT T-3， 
HBx一50: \_EcoRlJ\ 5'-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3'; 50一胸I—R: 5，-GAA TGC GGC CGC TTA CCC GTG 
GTC GGT CGG TAC-3’ 
HBx一51: 5\_EcoR\V: 5，-CCG AAT TCA CTA TGG CGC ACC TCT 
CTT TAG GCG; 154—漏一R: GAA TGC GGC CGC ATT AGG CAG 
AGG TGA AAA AGT T -3’ 
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HBx一 106: mjEcoRlJ: 5'-CCG AAT TCA CAA TGA CCG ACC 
TTG AGG CAT ACT T-3'; 154一胸I_R: 5'-GAA TGC GGC CGC ATT 
AGG CAG AGG TGA AAA AGT T-3' 
HBxJ36'. \_EcoR\J\ 5'-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3，； 136一颜-R: 5'-GAA TGC GGC CGC GCC TCC TAG 
TAG AAA GAC CTT-3' 
HBx一68: \_EcoRlJ: 5'-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3'; 154一層一R: 5'-GAA TGC GGC CGC ATT AGG CAG 
AGG TGA AAA AGT T-3 ‘ 
HBx一88: IJEcoRlJF: 5，-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3，； 154-胸I—R: 5'-GAA TGC GGC CGC ATT AGG CAG 
AGG TGA AAA AGT T-3’ 
The amplification was done by using the Expand High FidelityPLus PCR 
System (Roche Diagnostic GmbH, Mannheim, Germany). In a 40 
PCR reaction, the mixture contained 1.6 )j,l of primer pairs (0.8 [i\ from 
each primer of 10 pmol/|il) (Invitrogen, Carlsbad, CA)，4 [x\ of DNA 
template, 8 of 5X reaction buffer contains 7.5 mM MgCb (Roche 
Diagnostic GmbH, Mannheim, Germany), 4 p-l of2mM dNTPs and 0.4 p-l 
of enzyme blend which combined Taq DNA Polymerase and a novel 
protein that mediated proofreading activity (Roche, Diagnostic GmbH, 
Mannheim, Germany), and 22 |il of double distilled water (ddHaO). PCR 
program was set as follows: 
； 
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Steps PCR conditions Time 
1 95°C 3 mins 
2 95 °C 30 sec 
3 55 °C 30 sec 
4 72 30 sec 
5 Repeat step 2 to 4 for 35 cycles / 
6 72 °C 10 mins 
2.1.2 Agarose gel extraction 
Electrophoresis of the PCR products was done on a 1% agarose gel 
containing ethidium bromide in IX TBE buffer. QIAquick® Gel 
Extraction Kit (QIAGEN GmbH, Hilden, Germany) was used to purify 
the PCR product. The DNA fragments were excised from the agarose gel 
with a clean blade and the slices were weighed in a 1.5 ml eppendorf. 
Three volumes of Buffer QG was then added to 1 volume of gel and was 
incubated at 50°C for 10 minutes with constant vortex every 2-3 minutes 
during the incubation. One gel volume of 100% isopropanol was added 
to the samples after the gel was completely dissolved and mixed. The 
samples were then applied to the the QIAquick columns in 2 ml collection 
tubes and were centrifuged for 1 minute. The flow-through was discarded 
and 0.5 ml of Buffer QG to the same columns and was centrifuged for 1 
minute. 0.75 ml of Buffer PE with ethanol added before used was added 
to the columns and centrifuged for one minute. The flow-through was 
discarded and the columns were centrifuged for an additional 1 minute to 
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remove residual ethanol. The columns were placed into a clean 1.5 ml 
microcentrifuge tubes, and finally the DNA was eluted with 30 |j,l of H2O 
to the center of the QIAquick membrane and the columns were 
centrifuged at full speed for 1 minute. 
2.1.3 Restriction enzyme digestion 
The purified PGR products and the vector pcDNA3.1 (+) (Figure 2.2) 
(Invitrogen, Carlsbad, CA) were digested with restriction enzymes EcoRl 
(Promega, Madison, WI) and Not\ (Promega, Madison, WI). The 
multiple cloning sites (MCS) were shown in Figure 2.3. The reaction was 
carried out in a total volume of 30 |li1 in the following condition: 20 |il of 
PGR product or 1 |LI1 of vector, 3 |xl of 10-fold diluted BSA (Promega, 
Madison, WI), 3 |li1 of lOX buffer H (Promega, Madison, WI), 0.5 of 
EcoRl, 0.5 |Lil of Notl and desired volume of ddHzO. The reaction 
mixture was incubated in 37 for 3 hours. The digested products were 
then purified by agarose gel extraction as described in 2.1.2. 
2.1.4 Ligation of vectors and gene of interest 
The digested PGR products and the linearized pcDNAS.l (+) vector was 
ligated in a volume ratio of 10 : 3 (insert : vector). A reaction in total 
volume of 15 was done in the following condition: 10 [il of PCR 
product, 3 ]i\ of pcDNA3.1，1.5 |il of lOX ligation buffer and 0.5 i^l of T4 
DNA ligase (New England BioLabs Inc., Ipswich, MA). The mixture 
was incubated at 16 °C overnight. Eight HBx plasmids were obtained: 
pcDNA3.1, pcDNA3.1_x (full length HBx), pcDNA3.1_50 (mutant with 
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a.a. 1-50)，pcDNA3.1_51 (mutant with a.a. 51-154), pcDNA3.1_68 (Arg-
Pro insertion at a.a. 68)，pcDNA3.1—88 (Arg-Pro insertion at a.a. 88)， 
pcDNA3.1_106 (mutant with a.a. 106-154) and pcDNA3.1_136 (mutant 
with a.a. 1-136). 
2.1.5 Preparation of competent cells for transformation 
E.coli strain JM109 (Genotype: endA.\, recAl, gyrA96, thi, hsdRXl (!•「， 
mk")，re/Al, supEAA, A( lac-proAB\ [F' /raD36, proAR, /a^I^ZAMlS]) 
(Promega, Madison, MI) was used for transformation of the plasmids. 
The cells were grown in 100ml LB (Luria Bertani) medium (10 g 
Tryptone, 10 g NaCl, 5 g yeast extract per liter) at 2>TC shaker until the 
stage when O.D. reached 0.6 at 600nm. Then, they were separated into 2 
• . 
tubes and kept at 4°C for 15 minutes. Cell pellet was obtained by 
centrifuging the cultures at SOOOrpm for 5 minutes. After removing the 
supernatant, 10ml ice cold CaCb (50mM, pH7) were added to each tube 
and the cells were left in ice for 15 minutes. Before pelleting, the tubes 
were poured together and the mixture was centrifuging at SOOOrpm for 5 
minutes. The pellet was resuspended in CaCb (50mM, pH7) with 15% 
glycerol. The mixture was aliquoted into pre-chilled micro-centrifuge 
tubes and stored at -80°C. 
2.1.6 Transformation of plasmid in competent cell 
The E. coli strain JM109 (Genotype: endKX, recAl，gyrA.96, thi, hsdRXl 
(riT，mk+)，re/Al, •swpE44，^{lac-proAB\ [F' proAB’ 
27 
/a^I'^ZAMlS]) was used for the cloning of plasmids described in 2.1.4. 
These clones were transformed into the E. coli strain. 
Plasmids were introduced into JM109 by CaCb mediated transformation. 
The plasmids were incubated with the competent cells on ice for 10 
minutes. It was then followed by heat shock for 45 seconds and the 
DNA-competent cells mixture was put back to ice immediately for 2 
minutes. One milliliter LB medium was added to the cells and incubated 
at 37°C for 1 hour. The cells were then centrifuged at 6000 rpm for 1 
minute and were resuspended in 100 |xl of LB medium with lOOug/ml 
ampicillin. They were spread onto ampicillin containing agar (LBA) 
plates and incubated at 37°C overnight until single colonies could be 
isolated. 
2.1.7 Plasmid extraction by mini-prep 
The plasmids were extracted by following the protocol from QIAprep® 
Miniprep (QIAGEN GmbH, Hilden，Germany). A single colony was 
picked from each freshly streaked LBA plate and was inoculated in a 
culture of 5 ml of LB medium containing 100 ug/ml ampicillin. The 
cultures were then incubated at 37°C overnight with vigorous shaking at 
250rpm. After the shaking, the bacterial cells were harvested by 
centrifuging at 6000 rpm in a conventional, table-top microcentrifuge for 
3 minutes at room temperature. The pelleted bacterial cells were then 
resuspended in 250 of Buffer PI with RNase A solution added. The 
suspensions were transferred to a 1.5 ml microcentrifuge tube and 250 \i\ 
28 
of Buffer P2 was added to them. They were mixed thoroughly by 
inverting the tubes 4-6 times. Then, 350 |il of Buffer N3 was added to 
the lysates and was mixed immediately by inverting the tube 4-6 times. 
After that, they were centrifuged for 10 minutes at 13,000 rpm. The 
supernatants were applied to the QIAprep spin columns by pipetting and 
the columns were centrifuged for 1 minute. The flow-through was 
discarded. Each of the QIAprep spin column was washed by adding 0.5 
ml of Buffer PB and was centrifuged for 1 minute. Then, the column was 
washed by adding 0.75 ml of Buffer PE (with absolute ethanol added 
before used), and was centrifuged for 1 minute. The residual wash buffer 
was completely removed by centrifuging for an additional 1 minute. The 
QIAprep column was placed in a clean 1.5 ml microcentrifuge tube and 
the plasmid DNA was eluted with 30 i^l of elution buffer (10 mM Tris-Cl, 
pH 8.5) added to the center of each QIAprep spin column. The column 
was allowed to stand for 1 minute and then centrifuged for 1 minute to 
collect the DNA. 
2.1.8 DNA sequencing of the inserted gene 
The sequences of wild type and mutant HBx were checked by ABI 
PRISM™ BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit 
(Applied Biosystems, Foster City, CA). In each reaction, the following 
reagents were added: 200-500 ng of plasmid DNA as template, 8 |xl of 
terminator ready reaction mix, 1.6 pmol of T7 forward primer, 1.6 pmol 
of BGH reverse primer, and desirable amount of ddHaO to a total volume 
of 20 [i\. The mixture was placed in a thermal cycler GeneAmp PGR 
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System 9700 for 30 cycles: 96°C for 30 seconds, 5 5 f o r 5 seconds and 
60 °C for 4 minutes. The reaction was terminated at 4 °C until purifying. 
The purification steps were carried out by using spin columns. The gel 
material in the columns was tapped to the bottom and 0.8 ml of ddHsO 
was added. The upper cap was replaced and the columns were inverted 
several times to mix the water and gel material. The gel was then allowed 
to hydrate at room temperature for 2 hours and was allowed to settle after 
removing air bubbles by inverting and tapping. The columns were 
drained completely by gravity after removing the upper and lower end 
caps and were then inserted into the wash tubes. They were centrifuged 
at 730 g for 2 minutes to remove the interstitial fluid and were transferred 
to 1.5 ml microcentrifuge tubes. The reaction product was loaded to the 
top of the gel material and the columns were spun at 730 g for 2 minutes. 
The purified samples were collected in microcentrifuge tubes and were 
dried in a vacuum centrifuge for 15 minutes. Each sample pellet was 
resuspended in 12 of Template Suppression reagent. They were 
vortexed and spun before heating at 95 °C for 2 minutes to denature. The 
sequences of the fragments were then read by electrophoresis on the ABI 
PRISM 310 Genetic Analyzer. 
2.2 Transfection 
2.2.1 Cell line 
Human hepatic cell line Chang Liver (CL) (CCL-13) (ATCC，Manasas, 
VA) were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 
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high glucose (Gibco, Gran Island, NY), supplemented with 10% heat 
inactivated fetal bovine serum (FBS) (HyClone, Logan, UT) at 37�C，5% 
CO2. The cells were cultured in 100mm culture dish. 
2.2.2 Lipofectamine transfection 
The cells were transiently transfected with the wild-type and mutant HBx 
plasmids using the Lipofectamine™ Reagent (Invitrogen, Carlsbad, CA). 
3 X 10^  c e l l s were seeded into each well of 6-well culture plate to a total 8 
wells with complete medium one day before transfection. For each 
transfection sample, 2 |xg of plasmid DNA was diluted in 100 of 
DMEM without serum and mixed. Also, 8 |il of Lipofectamine™ was 
diluted in 100 )J•丨 of plain medium and mixed. The diluted DNA and 
diluted LipofectamineTM were mixed together and incubated at room 
temperature for 45 minutes. The complete medium was removed from 
the cells and replaced with 800 |xl of plain medium for each well. The 
diluted DNA-Lipofectamine complexes were then added to the wells and 
mixed gently. The cells were incubated in a CO2 incubator at 37 for 6 
hours. After the incubation, the transfection medium was aspirated and 
replaced with fresh, complete medium for growth. 
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2.2.3 Construction of Stably transfected cell lines 
Cells were incubated at 37 with 5% CO2 for 72 hours after transfection. 
They were then trypsinized and transferred to a 100 mm culture dish with 
selective medium for each transfection. They were selected with G418 
sulfate (Calbiochem，San Diego, CA) at a concentration of 400^ig/ml. 
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The selective medium was changed twice a week for a total period of 3 
weeks until single colonies could be seen and isolated. The dead cells 
and debris were removed at the same time. A few colonies from 
monolayer culture from each plate were isolated with paper discs and 
were transferred to 48-well plates with selective medium for clonal 
expansion. 
Eight polyclonal stable cell lines were obtained: CL_pcDNA3.1 (vector 
only transfected cells), CL_x (cells transfected with full length 
pcDNA3.1_x), CL_50 (cells transfected with pcDNA3.1—50)，CL_51 
(cells transfected with pcDNA3.1 一51)，CL_106 (cell transfected with 
pcDNA3.1_106), CL_136 (cells transfected with pcDNA3.1_136), 
CL_68 (cells transfected with pcDNA3.1_68)，CL_88 (cell transfected 
with pcDNA3.1_88). 
2.3 Detection of transfected gene at mRNA level by RT-PCR 
2.3.1 RNA extraction 
RNA was extracted from the stably transfected cell lines by using 
RNeasy® Mini Kit (QIAGEN GmbH, Hilden, Germany). The growth 
medium in culture dishes was aspirated and the cells were washed with 
phosphate buffered saline (PBS) (9.1 mM dibasic sodium phosphate, 1.7 
mM monobasic sodium phosphate, 150 mM sodium chloride, pH 7.4). 
They were then trypsinized and collected by adding medium containing 
serum to inactivate trypsin. The cells were transferred to 1.5 ml 
microcentrifuge tubes and centrifuged at 2000 rpm for 5 minutes. The 
• • 
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cell pellets were resuspended in PBS. They were then centrifuged again 
at 2000 rpm for 5 minutes and 350 \i\ RTL was added to the cell pellets. 
Ten mircoliters of p-mercaptoethanol (p-ME) was added to 1 ml of RTL 
buffer before use. The cells were lysed by vortexing and pipetting. The 
lysate was then homogenized by a QIAshredder spin column placed in a 2 
ml collection tube. After that, 350 of 70% ethanol was added to the 
homogenized lysate and mixed well by pipetting. The mixture was 
transferred to an RNeasy spin column placed in a 2 ml collection tube and 
was centrifuged at 8000g for 15 seconds. The flow through was 
discarded and 700 of Buffer RWl was added to the spin column. It was 
centrifuged again at 8000g for 15 seconds to wash the spin column 
membrane. The flow through was discarded, 500 \i\ of Buffer RPE with 
ethanol was added to the spin column and centrifuged at 8000g for 15 
seconds. The column was washed with 500 of Buffer RPE again and 
was centrifuged at 8000g for 2 minutes. It was centrifuged for an 
additional one minute at full speed to completely remove the ethanol. 
Finally, the spin column was placed in a 1.5 ml collection tube and the 
RNA was eluted with 30 |il of RNase free water. 
2.3.2 Reverse transcription-polymerase chain reaction (RT-PCR) 
cDNA was synthesized by reverse transcription (RT) and 9.75 jil of 
extracted RNA was added to a strip, and was incubated in GeneAmp PCR 
System 9700 at 70�C for 10 minutes. The reverse transcription was 
performed in a total volume of 20 in the following mixture: 9.75 |xl of 
.RNA, 2 of lOX reverse transcription buffer (Promega, Madison, WI), 4 
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of 25mM MgCl2 (Promega, USA), 2 of lOmM dNTP mix (Promega, 
Madison, WI), 0.5 …of rRNasin® RNase Inhibitor (40u/|il) (Promega, 
Madison, WI), 1 of random primers (500fxg/ml) (Promega, Madison, 
WI) and 0.75 |il of AMV-reverse transcriptase (10u/|il) (Promega, 
Madison, WI). The reaction was performed in the following condition in 
the PGR system: 
steps conditions Time 
1 Room temperature 10 minutes 
2 42�C 60 minutes 
3 99�C 5 minutes 
4 4 � C infinity 
The expression of wild type and mutant HBx was then checked by 
running PCR in specific primers: 
CL一X: l_EcoRl_¥: 5'-CCG AAT TCA ACC ATG GCT GCT AGG CTG 
TGC-3’； 154一胸I_R: 5'-GAA TGC GGC CGC ATT AGG CAG AGG 
TGA AAA AGT T-3' 
CL一50: l-EcoRlJ: 5，-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3'; 50一胸I_R: 5，-GAA TGC GGC CGC TTA CCC GTG 
GTG GGT CGG TAC-3' 
CL一51: Sl-EcoRl-F: 5’-CCG AAT TCA CTA TGG CGC ACC TCT 
CTT TAG GCG； 154一胸I一R: GAA TGC GGC CGC ATT AGG CAG 
AGG TGA AAA AGT T -3’ 
• • . .. . 
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CL一 106: W6—£coRl_F: 5'-CCG AAT TCA CAA TGA CCG ACC TTG 
AGG CAT ACT T-3'; 154一胸I—R: 5'-GAA TGC GGC CGC ATT AGG 
CAG AGG TGA AAA AGT T-3 ‘ 
CL_136: I一EcoRl-F: 5'-CCG AAT TCA ACC ATG GCT GCT AGG 
. > • 
CTG TGC-3'; 136一胸I-R: 5'-GAA TGC GGC CGC GCC TCC TAG 
TAG AAA GAC CTT-3' 
CL一68: 1 一Ecom—F: 5，-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3，； \54_Notl_R: 5’-GAA TGC GGC CGC ATT AGG CAG 
AGG TGA AAA AGT T-3' 
CL一88: \_EcoRl_¥: 5'-CCG AAT TCA ACC ATG GCT GCT AGG 
CTG TGC-3，； 154一漏一R: 5'-GAA TGC GGC CGC ATT AGG CAG 
AGG TGA AAA AGT T-3， 
The PGR was done in a volume of 10 i^l reaction mix which contained 2 
|il ofcDNA, 1 \i\ of thermophilic DNA polymerase lOX PGR buffer (Mg 
free) (Promega, Madison, WI), 1 of 2mM dNTPs (Promega, Madison, 
WI), 0.6 |lU of 25mM MgCb (Promega, Madison, WI), 0.8 i^l of primers 
(0.4 \x\ from each primer of 10 pmol/ |xl) (Invitrogen，Carlsbad, CA), 0.08 
of Taq DNA polymerase (Promega, Madison, WI), 4.52 [i\ of ddHaO. 
The PGR program was set as the following: 
Steps PCR conditions Time 
1 95�C 3 mins 
2 95 °C 30 sec 
3 55 °C 30 sec 
4 72�C 30 sec 
5. Repeat step 2 to 4 / 
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for 35 cycles 
6 72 °C lOmins 
2.3.3 Agarose gel electrophoresis 
After the PCR, the samples were loaded to a 1% agarose gel in TBE for 
electrophoresis. The size was checked to confirm expression of 
respective fragments. 
2.4 Detection of transfected gene at protein level by Western blot 
2.4.1 Sample preparation 
Total cell lysate was extracted for detection of HBx expression. For each 
cell line, 10^  cells were collected by trypsinization. The cells were 
washed twice by PBS and were centrifuged at 2000 rpm for 5 minutes. 
The PBS was aspirated and the cell pellet was resuspended with 500 of 
ice-cold RIPA buffer (IX PBS, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS) with 10 of protease inhibitors cocktail and 10 \i\ of PMSF 
(10 |ig/ml). The tubes were then incubated on ice for 30 minutes. After 
that, the cells were disrupted and homogenized by passing through 21G 
needle. Another 10 |il of PMSF was added to the lysate and was 
incubated on ice for 30 minutes again. The samples were centrifuged at 
1 OOOOg for 10 minutes at 4 and the supernatant was collected for assay. 
2.4.2 Measurement of protein concentration 
Protein concentration was determined by using Bio-Rad DC (detergent 
compatibility) Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA). 
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Reagent A' was formed by adding 20 of reagent S to 1 ml of reagent A. 
Five protein standards were prepared by serial dilution of 1.4 mg/ml 
bovine serum albumin (BSA) standard to construct the standard curve: 
125 |ig/ml, 250 |xg/ml, 500 |ig/ml, 1 mg/ml, 1.4 mg/ml. Five microliters 
of standards or samples were added to a microplate in duplicate and 25 |il 
reagent A' was also added. After that, 200 \x\ of reagent B was added and 
was mixed by shaking gently. The plate was incubated at room 
temperature for 15 minutes and absorbance was read at 750 nm in a 
microplate reader. Protein concentration of respective samples was 
calculated from the standard curve. 
2.4.3 Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-
PAGE) 
The SDS-PAGE was done with Mini-PROTEAN 3 Electrophoresis 
Module (Bio-Rad Laboratories, Inc., Hercules, CA). Protein samples 
were diluted with PBS to the desired concentration and 5X SDS loading 
buffer (60mM 4X Tris-Cl/SDS, 25% glycerol, 2% SDS, P-ME, 0.1% 
bromophenol blue) was added. The samples were incubated at 100°C for 
5 minutes and 30 \ig sample was then loaded to each lane of a 14% 
resolving polyacrylamide gel (3.5 ml of 40% acrylamide/Bis, 2.5 ml of 
4X Tris-Cl/SDS, pH 8.8，4 ml of H2O，10% APS, TEMED). Stacking gel 
of 5% was also set above the resolving gel (0.625 ml of 40% 
acrylamide/Bis, 1.25 ml of 4X Tris-Cl/SDS, pH 6.8，3 ml of H2O, 10% 
APS, TEMED). Ten microliters of Full-Range Rainbow Molecular 
Weight marker (Amersham Biosciences, Buckinghamshire, UK) was also 
37 
loaded to the gel as a protein size indicator. The protein was resolved 
with 120V for 2 hours. 
2.4.4 Transfer of proteins to the nitrocellulose membrane 
After electrophoresis, the gel was equilibrated in transfer buffer (25 mM 
Tris, 192 mM glycine, 20% methanol, pH8.3) for 5 minutes. The Hybond 
membrane (Amersham Biosciences, Buckinghamshire, UK), filter paper 
and fiber pads were also presoaked in transfer buffer. Then, the gel and 
the membrane were placed between two pieces of filter paper and two 
fiber pads (avoiding air bubbles formed between the gel and membrane), 
and were put in a tank containing ice-cold transfer buffer with an ice 
block. The protein was transferred from the gel to the membrane under 
lOOV for 1.5 hours. The whole transfer process was done at 4 
2.4.5 Immunoblotting of protein 
The membrane was equilibrated in Tris-buffered saline (200 mM Tris-Cl, 
137 mM NaCl, pH 7.5) with 0.1% Tween 20 (TBST) after protein transfer. 
It was then blocked in 5% non-fat milk for 1 hour. After that, the 
membrane was washed with TBST for 3 times, 5 minutes each. Then it 
was incubated with anti-HBx mouse monoclonal IgGi primary antibody 
(Affinity BioReagents, Inc., Golden, CO) (1: 1000 dilution) at 4 � C 
overnight. After incubation, the membrane was washed with TBST for 
10 minutes, and then 5 minutes each for 3 times before incubated with 
goat anti-mouse IgGi-HRP secondary antibody (1: 2000 dilution) (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 hour. The membrane 
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was again washed with TBST for 10 minutes, and 5 minutes each for 3 
times. It was then transferred to a flat surface for adding 1.5 ml of 
enhanced chemiluminescence system solution (ECL), formed by mixing 
reagent A and B (Amersham Biosciences, Buckinghamshire, UK). After 
1 minute incubation, the excess ECL solution was drained away and the 
membrane was wrapped with Saran-wrap. It was fixed in an x-ray film 
cassette with protein facing the Hyperfilm™ (Amersham Biosciences 
Buckingham-shire, UK), and was exposed for 1 minute. Finally, the film 
was developed in the film processor. 
• • . 
2.5 Measurement of reduced glutathione (GSH) concentration in cell 
lines 
2.5.1 Sample preparation 
The cells were trypsinized and 10^  cells were collected. They were 
resuspended with PBS and centrifuged at 600g for 5 minutes. The 
supernatant was removed and a packed cell pellet was obtained. Then, 25 
\i\ 5% sulfosalicylic acid (SSA) was added to the cell pellet and vortexed. 
The suspension was frozen and thawed twice using liquid nitrogen and 37 
°C water bath. After that, it was incubated on ice for 5 minutes to lyse the 
cells completely. The cell extract was centrifuged at lOOOOg for 10 
minutes at 4°C and the supernatant was collected. 
2.5.2 Measurement of GSH concentration 
Concentration of GSH in the samples was determined by using the 
modified Glutathione Assay Kit (Sigma-Aldrich, St. Louis, MO). 
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Glutathione standard stock solution (10 mM) was diluted 20-fold with 5% 
SSA to obtain a 500 |iM glutathione solution. Five glutathione standard 
solutions (31.25 i^M, 62.5 i^M, 125 i^M, 250 |iM, 500 i^M) were prepared 
by serial dilutions of the 500 |iM glutathione solution. The samples were 
diluted 3 times with 5% SSA before measurement. Ten micoliters of 
GSH standards or samples were pipetted into each well of a 96-well plate 
in duplicate and 150 working mixture (100 mM potassium phosphate 
buffer, pH 7.0，with 1 mM EDTA, 0.033 mg/ml DTNB) was then added 
to the wells with a multichannel pipette. It was mixed by pipetting up and 
down. The plate was incubated at room temperature for 5 minutes and 
the absorbance at 412nm was measurement with a microplate reader. The 
concentration of GSH of each sample was calculated from the standard 
curve. 
2.6 Superoxide dismutase (SOD) activity in cell lines 
2.6.1 Sample preparation 
Total protein lysate was obtained by method described in part 2.4.1 and 
protein concentration of the samples was determined by method described 
in 2.4.2. 
Mitochondrial protein was extracted by using the Mitochondria Isolation 
Kit for Cultured Cells (Pierce Biotechnology, Rockford, IL). Protease 
inhibitors were added to Reagent A and Reagent C immediately before 
use. Cells were collected in a total amount of 1 X 10^  by centrifuging 
harvested cell suspension in 1.5 ml eppendorf at 850g for 2 minutes and 
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the supernatant was removed. Then, 500 |il of Mitochondria Isolation 
Reagent A was added to the cell pellets and the samples were vortexed at 
medium speed for 5 seconds. The tubes were then incubated on ice for 
exactly 2 minutes. Ten microliters of Mitochondria Isolation Reagent B 
was added to the samples and were vortexed at maximum speed for 5 
seconds. The samples were incubated on ice for 5 minutes and they were 
vortexed at maximum speed every minute during the incubation. After 
that, 500 |Lil of Mitochondria Isolation Reagent C was added to the 
samples and the tubes were inverted several times to mix the content. 
The samples were centrifuged at 700g for 10 minutes at 4 °C. The 
supernatant was transferred to new eppendorf tubes and was centrifuged 
at 12000g for 15 minutes at 4 The supernatant was discarded and 
another 300 of Mitochondria Isolation Reagent C was added to the 
pellet. The samples were centrifuged at 12000g for 5 minutes and the 
supernatant was discarded. The pellets obtained were the isolated 
mitochondria. Finally, 50 i^l of 2% CHAPS in TBS (25 mM Tris, 0.15 M 
NaCI ； pH 7.2) was added to the mitochondrial pellets and were vortexed 
for 1 minute to lyse the mitochondria. 
2.6.2 Measurement of total SOD activity 
Total protein lysate was used to measure the total SOD activity. 50% 
Inhibition activity of SOD (IC50) was determined by using SOD 
determination kit (Fluka GmbH, Buchs, Switzerland). The samples were 
diluted to the same concentration (0.5)ig尔 1) with PBS. The working 
solutions in the assay were prepared by the following method. One 
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milliliter of WST Solution was diluted with 19 ml of Buffer Solution to 
get the WST working solution, 15 [l\ of Enzyme Solution was diluted 
with 2.5 ml of Dilution Buffer to get the Enzyme Working Solution. The 
reaction was performed in duplicate and 20 |xl of diluted samples was 
added to each sample well and blank 2 well (blank 2 was setup separately 
for each sample). After that, 20 \i\ of ddHsO was added to each blank 1 
and blank 3 well, and 200 |il of WST working solution was then added to 
each well in the 96-well microplate. The reaction mixture was mixed 
thoroughly. After that, 20 of Dilution Buffer was added to each blank 
2 and blank 3 well, and 20 \i\ of Enzyme working solution was added to 
• • 
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each sample and blank 1 well. The content was mixed thoroughly by 
constant shaking and the plate was incubated at 37 °C for 20 minutes. 
Finally, the absorbance was measured at 450 nm using a microplate 
reader. The SOD activity (inhibition rate %) was calculated according to 
the following equation: 
SOD activiy (inhibition rate%) 
={[(Ablankl-Ablahk3HAsample-Ablank2)]/(Ablankl-Ablank3)} X 1 0 0 % 
» 
2.6.3 Measurement of Cu/ZnSOD and MnSOD by Western blot 
The procedure was the same as described in 2.4.3 to 2.4.5. Total protein 
lysate and mitochondrial protein lysate was used to measure Cu/ZnSOD 
and MnSOD respectively. The amount of protein used was 5 |xg for 
Cu/ZnSOD and 10 i^g for MnSOD. Rabbit anti-Cu/ZnSOD polyclonal 
antibody (Stressgen Bioreagents, Victoria, Canada) was used in dilution 
of 1:4250 and anti-MnSOD mouse monoclonal IgGi (BD Biosciences, 
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San Jose, CA) was used in dilution of 1:1000 as primary antibody. Goat 
anti-rabbit IgG-HRP in a dilution of 1:4000 (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) and goat anti-mouse IgGi-HPR (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) in a dilution of 1:2000 were used as 
secondary antibodies respectively. Anti-p-tubulin rabbit polyclonal IgG 
(H-235) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-
VDACl (N-18) goat polyclonal IgG (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) were used as loading control for the samples 
respectively in a dilution of 1:2000. 
2.7 Cell proliferation assay 
2.7.1 Drugs and concentration 
Two chemotherapy drugs were used for studying cytotoxicity of drugs 
towards HBx-transfected cells. The working concentration of drugs was 
calculated based on the dose response curve at which the killing effect of 
the drugs was about 50% (IC50). Fluorouracil (5FU) (Sigma-Aldrich, St. 
Louis, MO) was diluted to a working concentration of 20 ng/ml and 
Doxorubicin (DOX) (Sigma-Aldrich, St. Louis, MO) was diluted to a 
working concentration of 50 ng/ml. 
2.7.2 MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyItetrazolium bromide) 
assay 
The cells were grown in complete DMEM in 37�C，5% CO2 until 80% 
confluence. They were then trypsinized and seeded into a 96-welI plate in 
a density of 5000 cells per well. The cells were allowed to grow 
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overnight. Different drugs were then added at the desired concentration 
in duplicate, two wells of each cell line were empty for blank control 
(Figure 2.5). The plates were then incubated in 37 for 48 hours and 10 
jil of MTT solution (Sigma-Aldrich，St. Louis, MO) was added to each 
well. They were returned to the incubator for another 4 hours to allow 
MTT to be metabolized. Finally, the medium was aspirated and 100 |al of 
DMSO (Sigma-Aldrich, St. Louis, MO) was added to resuspend the 
formazan dye. The plates were shaken gently and incubated in dark for 
30 minutes. Absorbance was measured at 560 nm with a background 
absorbance at 670 nm. 
2.7.3 Cell proliferation and cytotoxicity of the drugs 
Cell proliferation rate of different untreated HBx transfected cell lines 
was compared with non-transfected Chang Liver cells (CL). The 
following formula was used for calculation: 
Cell proliferation rate (%)= 
(Absorbance of untreated HBx transfected cells /Absorbance of CL) x 
100% 
Cytotoxicity of drugs (death rate %)= 
(1- Absorbance of drug treated cells/ absorbance of untreated cells) x 
100% 
2.8 Detection of apoptosis by flow-cytometry 
2.8.1 Cell culture 
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Control and different HBx transfected cells were seeded in 6-well plates 
at a density of 3 X 10^  cells per well and were allowed to grow overnight. 
Fluorouracil (5FU) and doxorubicin (DOX) was added at concentration of 
20 ng/ml and 50 ng/ml respectively and the plates were incubated at 37 °C, 
5% CO2 for 48 hours before collection. 
2.8.2 Cell fixation 
The medium in each well was collected in a 12 X 75 mm centrifuge tube. 
The cells were washed with 1 ml of PBS and the washing was also 
collected. They were then trypsinized and transferred to the respective 
centrifuge tubes. The cells were centrifuged at 2000 rpm for 5 minutes 
and were washed again with 1 ml of PBS. The supernatant was decanted 
and the cells were resuspended in 1% (w/v) paraformaldehyde in PBS, pH 
7.4 at a concentration of 1 X 10^  cells/ml. Then the cell suspension was 
placed on ice for 30 minutes. After that, the cells were centrifuged at 
2000 rpm for 5 minutes and the supernatant was discarded. They were 
washed with 2 ml PBS and centrifuged again at 2000 rpm for 5 minutes. 
The cell pellets were resuspended with 0.5 ml PBS and finally, 4.5 ml 
75% ice-cold ethanol (v/v) was added to the cells slowly with constant 
vortex. 
2.8.3 Cell staining 
The apoptosis of cells was measured by A P O - D I R E C T ™ Flow 
Cytometry Kit for Apoptosis (Chemicon, Temecula, CA). The fixed cells 
were centrifuged at 2000 rpm for 5 minutes and the 70% ethanol was 
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removed by aspiration. Then they were resuspended with 1 ml of wash 
buffer for each tube and were centrifuged again at 2000 rpm for 5 minutes. 
The supernatant was removed and the cells were washed with wash buffer 
repeatedly. After that, the cell pellets were resuspended in 50 of 
staining solution. The staining solution mix was prepared as follows: 
Staining solution component Volume (|il )(1 assay) 
TdT Reaction Buffer 10 
TdT Enzyme 0.75 
Fluorescein-dUTP 8 
Distilled water 32.25 
The cells were incubated in staining solution for 60 minutes at 37 in a 
temperature controlled bath and were shaken every 15 minutes for 
resuspension. One milliliter of Rinse Buffer was added to each tube after 
the incubation and the cells were centrifuged at 2000 rpm for 5 minutes. 
The supernatant was removed and the cells were washed by 1 ml of Rinse 
Buffer again. 
2.8.4 Flow cytometry analysis 
The cell pellets were resuspended in 0.5 ml of propidium iodide 
(PI)/RNase A solution. They were then incubated in dark for 30 minutes 
at room temperature and were analyzed by flow cytometry. 
2.9 Detection of protein involved in apoptotic pathway 
2.9.1 Antibodies 
46 
Antibodies used and their dilutions were listed below: 
Primary antibodies Dilution Secondary antibodies Dilution 
Actin (C-11) 1:1000 Bovine anti-goat IgG 1:2000~ 
goat polyclonal IgG HRP 
(Santa Cruz (Santa Cruz 
Biotechnology, Inc., Santa Biotechnology, Inc., 
Cruz, CA) Santa Cruz, CA) 
p-tubulin (H-235) 一 1 : 2 0 0 0 G o a t anti-rabbit IgG 1:4000 
rabbit polyclonal IgG HRP 
(Santa Cruz (Santa Cruz 
Biotechnology, Inc., Santa Biotechnology, Inc., 
Cruz, CA) Santa Cruz, CA) 
CIAP2 (H-85) 1:1000 Goat anti-rabbit IgG 1:4000 
rabbit polyclonal IgG HRP 
(Santa Cruz (Santa Cruz 
Biotechnology, Inc., Santa Biotechnology, Inc., 
Cruz, CA) Santa Cruz, CA) 
Bcl-2 (C-2) 1:1000 Goat anti-mouse IgGi 1:2000 
Mouse monoclonal IgGi HRP 
(Santa Cruz (Santa Cruz 
Biotechnology, Inc., Santa Biotechnology, Inc., 
Cruz, CA) Santa Cruz, CA) 
Table 2.1 List of antibodies used in apoptotic assay 
2.9.2 Sample Preparation 
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Total cell lysate: The procedure was the same as the one described in 
2.4.1. 
Nuclear protein extraction: 
Cells were collected and washed with PBS. Then, 300 of nuclear 
extraction buffer A (lOmM HEPES, pH 7.9; lOmM KCl; lOmM EDTA; 
1 OmM DTT; 0.4% NP40; protease inhibitor cocktail) was added to each 
samples and the tubes were shaken on a shaking platform at 150 rpm for 
10 minutes at 4°C. The samples were then centrifuged at 15000g for 3 
minutes at 4°C. The supernatant obtained was the cytosolic fraction. 
After that, 50 i^l of nuclear extraction buffer B (20mM HEPES, pH 7.9; 
0.4 M NaCl; ImM EDTA; 10% glycerol; lOmM DTT; protease inhibitor 
cocktail) was added to the pellets and the tubes were vortexed at 
maximum speed for 10 seconds to resuspend the pellets. Then the tubes 
were shaken vigorously at 200 rpm horizontally for 2 hours at 4�C on a 
shaking platform. The samples were then centrifuged at maximum speed 
for 5 minutes at 4°C. Finally, the supernatant was collected which 
contained the nuclear protein. 
Mitochondrial protein extraction: The procedure was the same as the one 
described in 2.6.1. 
2.9.3 Measurement of protein concentration 
The measurement of total protein and mitochondrial protein concentration 
is the same as described in 2.4.2. 
For measurement of nuclear protein concentration, Bio-Rad Protein Assay 
(Bio-Rad Laboratories, Inc., Hercules, CA) was used. The dye reagent 
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was prepared by diluting one part Dye Reagent Concentrate with four 
parts distilled water and was filtered to remove particulates. Four protein 
standards (1000 |xg/ml, 500 |ig/ml, 250 |ig/ml, 125 |xg/ml) were prepared 
by serial dilution from 1.4mg/ml BSA stock. The samples were diluted 5 
times to a concentration that fell within the linear range of the standards. 
Ten microliters of standards or samples were added to a 96-well plate in 
duplicate and 200|j.l of dye reagent was added to the wells with gentle 
shaking to mix the content. The plate was incubated at room temperature 
for 5 minutes and the absorbance was measured at 595nm. The protein 
concentration of samples was calculated from the standard curve. 
2.9.4 Western blotting 
The procedure was the same as described in 2.4.3 to 2.4.5. The 
antibodies used and their dilutions were listed in 2.9.1. 
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1321 ctcatcggaa ctgacaattc tgtcgtgctc tcccgcaagt atacatcatt t|ccatggct"^ 
13811 ctcggctgtg^gccaact g gatcctgcgc gggacgtcct ttgtttacgt cccgtcggcg 
1441 ctgaatcc^cggacgaccc ctcccggggc cgcttgg腿 tctaccgccc gcttctccgc 
1501 tctctttacg^^actcccc gtctgtgcct 
1561 tctcatctgc cggaccgtgt gcacttcgct tcacctctgc acgtcgcatg gagaccaccg 
1621 tgaacgccca cgggaacctg ccc^ggtct tgcataagag gactcttgga ctttcagcaa 
1681 tqtcaacqacl cqaccttqaq qcat^teca aagactgtgt gtttaatgag tgggaggagt 
1741 tgggggagga ggttaggttaj^g^tttg： tactag^gg;：昧gtaggcat aaattggtgt 
1801 gttcaccagc accatgGa^ i^j^ ;：i^ l:i^ g揮丨:::壊gg琪•#c: atctcatgtt catgtcctac 
Figure 2.1 Positions of primers using in amplifying the full length HBx and various 
mutants. The yellow arrows are forward primers and the red arrows are 
reverse primers. 
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Figure 2.2 Vector map of pcDNAS.l (+) 
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SomH I S.V/X I* |£c. |>R t| EcoR V fi.t/XI* | | Xho I 
9 2 9 D C A T C C A C T A G T C C A G T G T G G T G G A A T T C T G C X G A T A T C C A D C A C A ^ T G G C ^ G C C G C T C G 
A7>u I Dra n Ap^ I Pme I pcPKA3. l/BCiH fcvcc< primingiitc 
9 8 9 A G T C T A G A ' G G G C C C G Y T T A A A C C C G C T G A T ' C A G C C T C G A C T G T G C C F R C T A G T T G C C A G C 
1 0 4 9 C A T C T G T T G T T T G C C C C T C C C C C G T G C C T T C C T T G A C C C T G G A A G G T G C C A C T C C C A C T G 
BGHpalylA) Mtc 
1 1 0 9 T C C T T T C C I " A A T A A 1 < V A T G A G G A A A T T G C A T 
http://www.invitrogen.com/content/sfs/manuals/pcdna3. l_man.pdf 
Figure 2.3 Multiple cloning sites of pcDNAS.l (+). The restriction enzyme sites 
used are shown in red boxes. 
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Figure 2.4 Ligation of vector pcDNA3.1(+) and gene of interest. 
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Figure 2.5 MTT assay for cell proliferation and cytotoxicty of drugs. Cells were 
seeded at a density of 5000/weIl and drugs (5FU and DOX) were added 
according to the above diagram. 
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Chapter Three: Establishment of HBx transfected stable cell lines 
3.1 Introduction 
HBx has been demonstrated to be a multifunctional viral protein which is 
important for carcinogenesis in hepatocellular carcinoma. It has been 
reported that HBx protein includes both regulatory (a.a. 1-50) and 
transactivation domain (a.a. 51-154) which contains two Kunitz-type serine 
protease inhibitor domains at region a.a. 61 to 69 and 132 to 139 (Takada et 
al’ 1994; Gottlob et al, 1998). Specific domains in HBx were reported to be 
with different functions. Regions between a.a. 52 to 65 and 88 to 154 were 
important for HBx function in HBV replication (Tang et al, 2005). Regions 
between a.a. 102 to 136 and 111 to 154 were reported to bind p53 (Elmore et 
al, 1997; Lin et al, 1997). Region between a.a. 84 to 114 was reported to be 
the target domain to proteosome (Stohwasser et al, 2003). Different 
experiments have been done in different cell lines and systems to find out the 
effect of HBx on apoptosis. It has been shown in some experiments that HBx 
is pro-apoptotic in HCC (Terradillos et al, 1998; Tralhao et al, 2002; Lu and 
Chen, 2005; Kim et al, 2005; Su and Schneider 1997, Miao et al, 2005) while 
it is anti-apoptotic in others (Gottlob et al, 1998; Pan et al, 2001; Sirma et al, 
1999; Lee et al, 2001; Madden and Slagle, 2001). Also, HBx has been 
reported to be involved in different pathways and can interact with a number 
of genes and proteins such as p53 (Elmore et al, 1997; Lin et al, 1997; Doitsh 
and Shaul，1999). Since the effect of HBx on apoptosis is highly 
controversial, it is believed that different domains of HBx may play different 
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roles in apoptosis. Indeed, the locations of different domains responsible for 
carcinogenesis and transactivation are still under investigation. In order to 
determine the domain(s) which is/are responsible for oxidative stress and 
apoptosis in HCC, plasmids carrying wild type and different 
deletion/insertion mutants of HBx (Figure 3.1) were transfected into the 
hepatic cell line Chang Liver (CL) in this study. 
3.2 Results 
3.2.1 Plasmid construction 
Wild-type full length HBx gene (HBxjc) and different HBx genes with 
various mutations (HBx一50, HBxJI, HBxJS, HBx—88, HBx J 06, HBx一13 6) 
were amplified by PGR using different primer pairs (listed in 2.1.1). The 
corresponding sizes of these PGR products were shown in Figure 3.2. 
HBx—50 showed a band of 174bp (lane 2), HBx—51 showed a band of 336bp 
(lane 3)，HBx一68 and HBx_88 showed a band of 493bp (lane 4 and 5)， 
HBx—106 showed a band of 171bp (lane 6)，HBx�36 showed a band of 
432bp (lane 7) and full length HBx showed a band of 487bp (lane 8). 
Various HBx fragments amplified by PGR were digested by restriction 
enzymes EcoRl and Not\, and were ligated with mammalian expression 
vector pcDNA3.1(+) digested by the same restriction enzymes. The plasmids 
constructed were confirmed by PCR amplification using T7 forward and 
BGH reverse primers as shown in Figure 3.3. The sizes of amplicons of 
56 
pcDNA3.1, pcDNA3.1 一 5 0， p c D N A 3 . 1 — 5 1， p c D N A 3 . 1 _ 6 8 , pcDNA3.1_88, 
pcDNA3.1 一 106，pcDNA3.1-136 and pcDNA3.1_x were 159bp (lane 2)， 
282bp (lane 3), 444bp (lane 4)，600bp (lane 5)，600bp (lane 6)，279bp (lane 
7)，540bp (lane 8) and 594bp (lane 9) respectively. The plasmids were 
further checked by DNA sequencing to confirm the sequences were correct 
(Appendix 1). 
3.2.2 Stable transfection of cell lines 
The plasmids constructed were transfected into the Chang liver (CL) cell line 
using lipofectamine reagent. In order to obtain stable cell lines, the 
transiently transfected cells were treated with G418 at 400 i^g/ml for 
selection until stably transfected cell lines were obtained. 
The mRNA expression of wild type and mutant HBx gene in the cells was 
confirmed by RT-PCR with respective primers mentioned in section 2.3.2. 
Hepatoma ceil line Hep3B (ATCC，HB-8064) expressing the HBx gene was 
used as a positive control (Lane 2) (Figure 3.4 A). CL_pcDNA3.1 (lane 2) 
showed no band while CL—50 (lane 3), CL_51 (lane 4)，CL_68 (lane 5)， 
CL_88 (lane 6)，CL_106 (lane 7)，CL_136 (lane 8) and CL_x (lane 9) show a 
single band at 174bp，336bp, 493bp, 493bp, 171bp, 432bp and 487bp 
respectively (Figure 3.4 B). 
The protein expression of full-length and mutant HBx was also confirmed by 
Western blot with ABR's mouse anti-HBx antibody (clone X36C) as shown 
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in Figure 3.5. Protein extract from Hep3B was used as a positive control. 
CL (lane 1) and CL_pcDNA3.1 (lane 2) showed no HBx expression. The 
full-length HBx (lane 9) and the two insertion mutants CL_68 (lane 5) and 
CL一88 (lane 6) showed a band at size of approximately 17kDa. However, 
the protein expression of other deletion mutants CL_50 (lane 3)，CL_51 (lane 
4)，CL_106 (lane 7) and CL_136 (lane 8) cannot be detected as the epitope 
for antibody binding maybe truncated or the protein was too small to be 
detected. The positive control Hep3B also showed a band at 17kDa (lane 10). 
3.2.3 Morphology of wild type and mutant HBx-transfected cell lines 
The morphology of different HBx-transfected cells was shown in Figure 3.6. 
Non-transfected CL was adherent epithelial cells. The cells that were 
transfected with fiill length HBx (CL_x) formed colonies of tightly cohesive 
epithelial cells that had round larger nuclei when compared with the non-
transfected CL and CL_pcDNA3.1. On the other hand, CL一50 showed a 
more fibroblastic morphology when compared with the negative control CL. 
The morphology of CL一51，CL一68，CL_106 and CL一 136 was similar to that 
of CL but they have a rounder nuclear which appeared to be apoptotic. 
Further experiments including the MTT cell proliferation assay and TUNEL 
assay were used to prove the cells being more susceptible to apoptosis. 
3.3 Discussion 
Since HBV integration is usually found in HBV-induced HCC and HBx gene 
is often mutated, it is important to set up human hepatic cell lines which 
58 
stably expressing wild-type HBx and its mutants to study the effect of HBx 
on liver cells. 
The different plasmids were designed and constructed according to the 
functional domains of HBx reported (Gottlob et al, 1998). pcDNA3.1_50 
expresses the N-terminal regulatory domain of HBx while pcDNA3.1_51 
displays the C-terminal two-thirds transactivation domain of HBx. Among 
the transacticvation domains, there were two Kunitz serine protease 
inhibitors and some specific regions which were thought to be crucial for 
transactivation and apoptosis in HCC. pcDNA3.1_68 and pcDNA3.1_88 
expresses a full length HBx in which Arg-Pro was inserted at positions 68 or 
88. The intact sequence at 68 and 88 was thought to be the essential domains 
for transactivation (Gottlob et al, 1998). pcDNA3.1_106 expresses the C-
terminal one-third transactivation domain and pcDNA3.1_136 the N-terminal 
two-thirds including the regulatory domain and part of the transactivation 
domain. 
Stably transfected cell lines expressing wild type and mutated HBx were 
successfully constructed. Chang Liver (CL) cell line is originally thought to 
be derived from human normal liver tissue but was found to be contaminated 
with HeLa cells. It has an adherent epithelial morphology. It was used in 
this study because it was thought to be derived from normal liver tissue and 
HBx was not expressed in this cell line. Thus, the effects of the transfected 
HBx genes and its mutants on the cells could be interpreted. Also, it was a 
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normal liver cell lines. Though it is HeLa contaminated to allow propagation 
during culture, the effect of carcinogenesis of HBx can be studied. 
Although transient transfection often results in high level of expression of the 
introduced gene, stably transfected cell lines were chosen and used in this 
project. There were three advantages for using stably transfected cell lines in 
this study. Firstly, HBx is often integrated in the host genome during 
carcinogenesis of HCC, so it can better imitate the condition in vivo because 
the HBx gene was integrated into the host DNA and replicated during cell 
division. Secondly, the gene expression could last for a longer period with a 
suitable selectable marker. Thirdly, the transfection efficiency between each 
cell lines could be different during transient transfection. However, in stable 
transfection, it was supposed that all cells were carrying the HBx gene with 
G418 selection. 
However, the transfected gene may probably be maintained as an episome 
instead of integrated into the host genome during the early stage of stable 
transfection, so it may lose easily or affect the properties of the expressed 
HBx. Also, the expression of the transfected gene could be much lower than 
that of transient transfection because usually one in lO* transfected cells will 
have the gene stably integrated into the host genome. 
The morphology of the cells transfected with full length HBx and various 
mutants was different. In figure 3.6，we can see that CL_50 shows a more 
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fibroblastic morphology, while CL_51, CL_68, CL_106, CL_136 and CL_x 
show rounder and larger nuclei when compared with CL. Though the 
morphology of cells alone does not necessarily indicate whether the cells are 
undergoing apoptosis or not, cell morphology may indicate the status of the 
cells. Cells with a more fibroblastic shape usually have a higher proliferation 
rate while cells with a rounder shape and rounder nuclei usually grow slower 
and are more likely to be apoptotic. 
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Figure 3.1 Schematic representations of wild-type HBx (HBx_x), and its mutants 
H B x 一 5 0 ， H B x 一 5 1 ， H B x 一 6 8 ， H B x — 8 8 , H B x 一 1 0 6 a n d H B x 一 1 3 6 . 
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Figure 3.2 PCR products of full-length HBx gene and various HBx mutants. 
Lane 1 is 100 bp DNA marker, lane 2 is HBx一50, lane 3 is HBx一51, lane 4 
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Figure 3.3 Confirmation of plasmids construction of different HBx genes ligated with 
mammalian vector pcDNA3.1(+) using T7 forward and BGH reverse 
primers. Lane 1 is lOObp DNA marker, lane 2 is pcDNAS.l (159bp), lane 
3 is pcDNA3.1_50 (282bp), lane 4 is pcDNA3.1 一5 1 (444bp)，lane 5 is 
pcDNA3.1 一 6 8 (600bp), lane 6 is pcDNA3.1_88 (600bp), lane 7 is 
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Figure 3.4 mRNA expression of wild type HBx and its mutants in Hep3B and stably 
transfected Chang Liver (CL) confirmed by RT-PCR. (A) Lane 1 is lOObp 
DNA marker, lane 2 is positive control Hep3B (462bp). (B) Lane 1 is 
lOObp DNA marker, lane 2 is CL_pcDNA3.1 (no band), lane 3 is CL—50 
(174bp), lane 4 is CL_51 (336bp)，lane 5 is CL_68 (493bp), lane 6 is 
CL_88 (493bp), lane 7 is CL_106 (171bp)，lane 8 is CL_136 (432bp) and 
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Figure 3.5 Protein expression of HBx and its mutants in Chang Liver (CL) and Hep3B. 
Lane 1 is CL (no band), lane 2 is CL_pcDNA3.1 (no band), lane 3 is 
CL一50 (no band), lane 4 is CL—51 (no band), lane 5 is CL_68 (17kDa)， 
lane 6 is CL_88 (17kDa)，lane 7 is CL_106 (no band), lane 8 is CL_136 (no 
band), lane 9 is CL_x (17kDa) and lane 10 is Hep3B (17kDa). 
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Chapter Four: Antioxidant level in HBx transfected cell lines 
4.1 Introduction 
HBx has been proven to be associated with oxidative stress and it affects 
antioxidant levels. But the mechanism of how HBx is involved in oxidative 
stress is not fully known. In a previous report, HBx was proven to activate 
transcription factors such as STAT-3 and NF-kB through oxidative stress 
(Waris et al, 2001). Also, it has been reported that the antioxidant level of 
liver was altered with chronic HBV infection or HCC (Chrobot et al, 2000; 
Yang et al, 2005; Bolukbas et al, 2005). 
Antioxidants can scavenge free radicals such as reactive oxygen species 
(ROS) to prevent the harmful effects to the cells. There are two broad types 
of antioxidants: non-enzymatic molecules and enzymatic scavengers. The 
non-enzymatic antioxidants include glutathione (GSH), vitamin A, C and E, 
and flavenoids. The enzymatic ones include superoxide dismutase (SOD), 
catalase and peroxidase (Martindale and Holbrook，2002). Oxidative stress 
occurs when the level of free radicals exceeds the level of antioxidants. 
Different concentrations of ROS can elicit different responses to the cells. 
Low dose of ROS can promote cell proliferation, however intermediate dose 
or high dose of ROS can cause cell growth arrest or even cell death 
(Martindale and Holbrook, 2002). In order to protect the cells from damage 
and cell death, antioxidants are often induced. However, it is believed that 
drug resistance in cancer cells maybe due to the high level of antioxidants 
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which prevents apoptosis or necrosis during chemotherapy. Therefore, the 
high level of antioxidants may not be an advantage in cancer therapy 
(D'Andrea, 2005). 
In this project, the concentration of GSH and the activity of SOD in different 
HBx transfected cell lines were measured as an indicator of oxidative stress 
and cellular antioxidant capacity. 
GSH is a tripeptide (y-glutamylcysteinylglycine) which is the major free thiol 
present in cells. It is a major antioxidant and can remove free radical 
(Akerboom and Sies，1981). Glutathione is present mainly in reduced form 
(90%-95%) inside the cells and GSSG is formed after when GSH is oxidized. 
GSH can be an indicator of overall health of a cell although high GSH 
concentration in cells could be pathological (Nair et al, 1991). In our study, 
the concentration of GSH was measured by a modified colorimetric method 
using Sigma's Glutathione Assay Kit. The reaction was based on the redox 
reaction between glutathione disulfide (GSSG) and GSH. Originally, the kit 
is designed to measure the total glutathione (GSSG + GSH) in the biological 
samples, but we have modified the procedure to just measure GSH for a 
better assessment of antioxidant status in cells. The reaction equation is as 
the following: 
2 GSH + DTNB 一 GSSG + 2 TNB 
The yellow product 5-thio-2-nitrobenzoic acid (TNB) generated is directly 
proportional to the concentration of GSH in the samples (Nair et al, 1991). 
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Superoxide dismutase (SOD) is present in cells in two major forms, the 
Cu/ZnSOD and MnSOD. Cu/ZnSOD is present in the cytosol while MnSOD 
is present in the mitochondria. SOD is also a major antioxidant in biological 
system and it catalyzes the dismutation of superoxide into oxygen and 
hydrogen peroxide. It has been reported that lacking Cu/ZnSOD leaded to 
oxidative damage and hepatocarcinogenesis (Elchuri et al, 2005). In this 
project, the total SOD activity was measured indirectly by using Fluka's 
SOD Determination Kit. The WST solution (2-(4-Iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) is a 
highly water-soluble tetrazolium salt that will produce a water-soluble 
formazan dye when it is reduced by a superoxide anion. The rate of 
reduction with O2 is positively related to xanthine oxidase (XO) activity and 
is inhibited by SOD (Figure 4.1). So, the SOD activity can be calculated 
indirectly by determining the I C 5 0 (50% inhibition activity of SOD) using a 
colorimetric method. 
4.2 Results 
4.2.1 Glutathione (GSH) concentration in different cell lines 
The concentration of GSH in different HBx transfected cell lines was 
measured by Glutathione Assay Kit. The mean concentration was calculated 
with seven individual experiments and the GSH concentration in each cell 
lines was compared with the negative control CL by independent samples t-
test. The result is shown in Figure 4.2. CL_pcDNA3.1 (also negative 
70 
control), CL一50, CL一88 and CL一 136 did not show much difference in GSH 
levels compared with CL. On the other hand, CL_x had the highest GSH 
concentration, with an increase of about two folds, when compared with the 
negative control (CL) (p<0.001). CL_51 and CL—106 also showed a 
significantly higher GSH concentration than CL (p<0.05), with an increase of 
about 1.5 folds. Although CL—68 did not show a statistical difference in 
GSH concentration compared with the control ((p=0.053), the concentrations 
of GSH in tended to be increased. 
4.2.2 Superoxide dismutase (SOD) activity in different cell lines 
4.2.2.1 Total SOD activity 
The inhibition activity of SOD ( I C 5 0 ) in different HBx transfected cell lines 
was measured by SOD Determination Kit. The total SOD activity in the cells 
was approximately proportional to the inhibition activity of SOD. The mean 
of SOD activity was obtained from eight independent experiments. Each cell 
lines were compared with the negative control CL using independent samples 
t-test. However, the total SOD activity did not show significant difference 
between cell lines (Figure 4.3). 
4.2.2.2 Cu/Zn SOD 
The level of Cu/ZnSOD protein was assessed by Western blotting using 
rabbit anti-CuZnSOD polyclonal antibody. Cytosolic fraction of protein was 
used in the experiment. The Cu/ZnSOD in different cell lines did not show 
much difference (Figure 4.4). 
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4.2.2.3 MnSOD 
The level of protein expression of MnSOD was also assessed by Western 
blotting using mouse anti-MnSOD IgGl antibody. Mitochondrial extract 
was used in the blotting. The level of expression was found to be increased 
in CL—68, CL_106 and CL一 136 when compared with other cell lines (Figure 
4.5). 
4.3 Discussion 
HBx clearly affects the level of GSH in CL and the C-terminal may be 
responsible for the effect of HBx. However, the expression of another major 
antioxidant SOD is not significantly altered by HBx. 
GSH was chosen to be an indicator for the antioxidant capacity in the present 
study because the GSH is the most important antioxidant in human liver and 
its level has been shown to be in the highest concentration in liver cells, 
compared with other antioxidants such as vitamin C and E (Evelson et al’ 
2001). SOD (Cu/ZnSOD and MnSOD) is a major antioxidant in various cells 
including liver cells. The level of SOD has been reported to be related to 
HCC (Elchuri et al, 2005) and its mitochondrial location may position itself 
as a regulator to control cell growth and apoptosis (Kahlos, 1999). 
Antioxidants levels may reflect the health situation of the cells. Antioxidants 
are necessary for protection of cells from damage by free radicals. However, 
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high level of antioxidants does not necessarily represent healthy (Nair et al, 
1991). A healthy cell maintains the antioxidant at a certain consistent level. 
Sometimes, if the antioxidant level is extremely high or higher than normal, 
it may actually reflect the relatively unhealthy situation of the cells. 
t 
The level of GSH in liver cells is believed to be highly related to oxidative 
stress inside the cells (Balendiran et al, 2004; Estrela et al, 2006). When the 
level of ROS increases, the concentration of GSH may be induced to a higher 
level to scavenge the ROS produced. The induction of GSH and other 
antioxidant acts like a positive feedback and compensation system to keep a 
healthy balance between oxidants and antioxidants in the cells. However, 
when the production of ROS is too much to be scavenged by the antioxidants, 
that is, the highest antioxidant capacity has been reached, oxidative stress and 
cell damages may still happen. 
Though the expression of Cu/ZnSOD which is present mostly in the cytosol 
was not altered in HBx transfected cell lines，MnSOD which is present 
mainly in the mitochondria showed different expression level in different cell 
lines. The increased expression of MnSOD in CL一68 and CL_106 coincides 
with that of GSH in the same sets of cells. However, the expression level of 
CL_x which has the highest GSH concentration did not show higher MnSOD 
expression. This suggests that HBx may affect GSH and MnSOD by 
different mechanisms. The level of MnSOD may be altered by another 
domain in the C-terminal of HBx. The level of MnSOD may play a role in 
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mitochondrial-mediated apoptosis since MnSOD is present in mitochondria 
mainly (Oberley and Buettner, 1979). It is possible that certain forms of HBx 
may directly penetrate into the mitochondria to disturb the SOD system or 
they may indirectly influence SOD by activating some transporters which can 
travel into the mitochondria. But the mechanism still needs further 
investigation. 
There are different reports on the GSH level and SOD activity in HCC and 
other cancer models. It has been reported that the expression level of 
Cu/ZnSOD and MnSOD is higher in well-differentiated HCC cell lines such 
as HepG2 and Hep3B (Yang et al, 2005). Also, the GSH level was found to 
be increased by two-fold in some HCC specimens when compared with 
normal liver tissues (Huang et al, 2001). In other cancers, GSH levels has 
been found to be elevated in a number of drug-resistance tumor cells: bone 
marrow (Joncourt et al, 1995), breast (Perry et al, 1993)，colon (Redmond et 
al 1991; Berger et al, 1994)，larynx (Mulder et al’ 1995)，lung (Cook et al, 
1991; Oberli-Schrammli et al, 1994), prostate (Bailey et al, 1992) and 
ovarian cancers (Britten et al, 1992). For SOD activity, cancer cells such as 
lung fibroblasts were found to have a higher acitivity of SOD than that in the 
normal lung cells (Oberley and Buettner, 1979). 
A high antioxidant level, especially GSH, often leads to resistance of tumor 
cells to chemotherapy or radiotherapy (D'Andrea, 2005). There have been 
reports that overexpression of glutathione S-transferase (GSTs) and elevated 
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GSH levels are usually related to resistance to chemotherapeutic drugs 
(Balendiran et al, 2004). In some cancer models, it was suggested that 
antioxidants should be avoided by patients during chemotherapy. For 
example, trials have been conducted comparing placebo to vitamin C in 
patients with cancer and shown worse survival rate in vitamin C group 
(Creagan et al, 1979; Moertel et al, 1985). But a low GSH level can protect 
the cells from oxidative damage and still sensitive to the killing of 
chemotherapeutic drugs (Reliene and Schiestl, 2006). 
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Figure 4.1 Principle of SOD Assay using WST solution, calculating the inhibition 
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Figure 4.4 Level of protein expression of Cu/ZnSOD in different HBx transfected cell 
lines. There is no difference in Cu/ZnSOD expression between different 
cell lines. It shows a band of 23kDa which is the molecular weight of 
Cu/ZnSOD. Lane 1 is CL, lane 2 is CLjpcDNA3.1, lane 3 is CL_50, lane 
4 is CL一51, lane 5 is CL_68, lane 6 is CL一88，lane 7 is CL一 106, lane 8 is 
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Figure 4.5 Level of protein expression of MnSOD in different HBx transfected cell 
line. The protein expression of MnSOD is higher in CL_68, CL一 106 and 
CL_136. It shows a band of 25kDa which is the molecular weight of 
MnSOD. Lane 1 is CL, lane 2 is CL_pcDNA3.1, lane 3 is CL—50，lane 4 is 
CL一51，lane 5 is CL一68，lane 6 is CL_88, lane 7 is CL_106，lane 8 is 
CL_136 and lane 9 is CL一x. 
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Chapter Five: Involvement of HBx in apoptotic pathway 
5.1 Introduction 
HBx is believed to be involved in apoptotic pathway. Both apoptotic and 
antiapoptotic properties of HBx has been reported. Whether HBx is 
apoptotic or antiapoptotic depends on the balance between the signals of viral, 
cellular and environmental origin (Bergametti et al, 1999; Diao et al, 2001). 
Also, different domains of HBx are believed to be responsible for the 
different properties of HBx. It has been shown that the C-terminal of HBx is 
responsible for transactivation and the replication of HBV (Tang et a/, 2005). 
It has also been suggested that the C-terminal is responsible for apoptosis (Tu 
et al, 2001) while the regulatory N-terminal is dispensable for apoptosis 
(Murakami era/, 2001). 
t • 
In the cytotoxicity assay of drugs, 5-fluorouracil (5FU) and doxorubicin 
(DOX) were used. 5FU belongs to anti-metabolites chemotherapeutic drugs. 
It binds to an enzyme inside cancer cells called thymidylate synthetase which 
catalyzes the synthesis methylation of dUMP in the pyrimidine pathway and 
inhibits its action. It blocks the synthesis of pyrimidine which is important in 
DNA replication (Tirgan, 1996). DOX is a cytotoxic chemotherapy agent. It 
is a DNA interacting drug which intercalates DNA but the mechanism is not 
fully known (Fomari et al, 1994). It is believed to interact with DNA and 
inhibit macromolecular biosynethesis. It stabilizes the topoisomerase II 
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complex which unwinds DNA and prevents DNA double helix being 
resealed and hence stops the replication (Momparler et al，1976). 
Since the function of HBx in apoptosis is diverse, it is difficult to predict 
which pathway it follows. In the previous experiments, it has been shown 
that HBx altered the glutathione concentration and expression level of 
MnSOD, the role HBx plays in apoptosis maybe related to oxidative stress. 
NF-KB has been reported to be a biomarker of oxidative stress in vitro and in 
vivo (van den Berg et al, 2001) and it has been reported to be activated by 
HBx through oxidative stress (Waris et al, 2001). Also, NF-KB activity has 
been proven to be deregulated in many cancers and transcriptionally activates 
the expression of anti-apoptotic proteins Bcl-2 and lAP families (Baldwin, 
2001). Therefore, the two anti-apoptotic protein cIAP2 and Bcl-2 was 
chosen to be the targets to assess the role of HBx plays in the apoptotic 
pathway. 
5.2 Results 
5.2.1 Cell proliferation of HBx transfected cells 
The cell proliferation rate of different HBx transfected cell lines was 
compared with the negative control CL and CL_pcDNA3.1 by using the 
MTT cell proliferation assay. The cell proliferation rate of CL was defined 
to be 100%. Values higher than 100% represented an increase in cell 
proliferation rate than CL while values lower than 100% represented a 
decrease in cell proliferation rate. The mean proliferation rate was calculated 
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on five independent experiments. The results were presented in mean 土 
standard deviation (SD) and the statistical analysis was performed by 
independent samples t-test comp^ed with CL. The results were considered 
statistically significant when p-value is smaller than 0.05. 
The results are shown in figure 5.1. CL_50 showed a significantly higher 
proliferation rate of 120.91% (p=0.003) while CL_51, CL一68，CL一 106， 
CL_136 and CL_x showed a significantly lower proliferation rate of 80.02% 
(p=0.002), 87.23% (p=0.002), 84.66% (p=0.011), 80.14% (p=0.004) and 
66.96% (p=0.002) respectively. CL一88 showed a similar proliferation rate 
when compared with negative control of 95.84% (p=0.312) (Figure 5.1). 
5.2.2 Apoptosis of HBx-transfected cells 
The level of apoptosis of different HBx-transfected cells was detected by 
TUNEL assay using flow cytometry. The results were shown in Figure 5.2. 
If the peaks shifted more to the right, it indicates more number of cells die in 
apoptosis. From the diagrams, there were a large number of apoptotic cells 
in CL_51, CL_68 and CL_x, the percentage of apoptotic cells were 69.72%, 
65.4% and 71.79% respectively. On the other hand，CL_106 and CL一136 
also show some degree of apoptosis, the percentage of apoptotic cells were 
7.71% and 15.31% respectively. However, CL_50 and CL_88 did not show 
obvious apoptosis, with percentage of apoptotic cells of only 5.76% and 




5.2.3 Cytotoxicity of fluorouracil (5FU) and doxorubicin (DOX) in HBx 
transfected cells 
The cytotoxicity of the two chemotherapy drugs 5FU and DOX was assessed 
by MTT assay which showed the percentage of cell death compared with the 
untreated cell lines individually. The results were calculated on four 
independent experiments and they were presented in mean 土 SD. Statistical 
analysis was performed by independent samples t-test compared with CL and 
was considered significant when P<0.05. 
The percentage of cell death of CL_x was less than that of the negative 
control in both 5FU and DOX treatments. For the drug 5FU, CL_x showed a 
lesser percentage of cell death with only 25.4% (p=0.009) when compared 
with the control CL (38.4%). For the drug DOX, CL_x also showed a lesser 
percentage cell death with only 30.0% (p=0.033) when compared with the 
negative control CL (40.2%). However, the difference was not statistically 
significant in other mutant HBx-transfected cell lines (Figure 5.3). 
5.2.4 Detection of anti-apoptotic proteins cIAP2 and Bcl-2 in HBx-transient 
and stably transfected cells 
The levels of the anti-apoptotic proteins cellular inhibitor of apoptotic protein 
(cIAP2) and Bcl-2 were studied in different HBx transfected cell lines by 
Western blotting. 
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In transient transfection, the expressions of the two anti-apoptotic proteins 
cIAP2 and Bcl-2 were significantly higher in CL_51 and CL_68 when 
compared with the negative control (Figure 5.4). However, there was not 
much difference in the levels of cIAP2 and Bcl-2 in stable transfection 
(Figure 5.5 A, B). 
5.3 Discussion 
Different degrees of cell proliferation and apoptosis were observed in cell 
lines transfected with full length HBx and various mutants. From our results, 
cell lines that have a lower proliferation rate such as CL_x, CL_51, CL_68, 
. CL_106 and CL一 136，also give a higher apoptotic rate. 
The whole C-terminal (a.a. 51-154) of HBx may be essential for apoptosis in 
hepatic cells since the cell line with only N-terminal (a.a. 1-50) of HBx had 
the highest proliferation rate and did not show any sign of apoptosis. The 
specific region in C-terminal which was essential for apoptosis could not be 
found, but a.a. 88 was shown to be essential for the apoptosis as the apoptotic 
property of HBx was loss when it was mutated. On the contrary, a.a. 68 is 
dispensable for apoptosis because there are still apoptotic cells even if it is 
mutated. 
Drug resistance was generally not seen in the cell lines transfected with HBx 
mutants when compared with the negative control. But there was significant 
degree of drug resistance seen in cell line transfected with wild type HBx 
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(CL一X) which has the highest concentration of GSH. Thus the high 
concentration of GSH may contribute to the drug resistance seen in CL_x. 
CL-x cells may thus be protected from the cytotoxic effect produced by the 
drugs. 
However, the mechanism of how GSH is related to the insensitivity of the 
liver cells to the killing of chemotherapeutic drugs (5FU and DOX) is not 
fully understood. It has been proposed by some papers that the drug 
resistance is arisen via GSH conjugation and detoxification (phase II 
detoxification), which involve the mechanisms of GSH, GSH transferase 
(GST) and glutathione S-conjugate export pump (GS-X pump) (Ishikawa, 
1992; Suzuki et al, 2001). Also, multi-drug resistance protein 5 (MRP5) may 
affect the function of GS-X pump which can eliminate anticancer chemicals 
via intracellular conjugation with GSH catalyzed by GST (Suzuki et al, 2001; 
De Bittencourt et al, 1998). In a study, GSH was proven to be a rate-limiting 
factor to cisplatin cytotoxicity in HepG2 cells (Zhang et al, 2001). So, high 
concentration of GSH rather than GST or GS-X pump maybe the major 
factor which causes drug resistance in liver cancer. If drug resistance is 
proven to be highly related to high level GSH, chemicals which inhibit GSH 
synthesis, such as buthionine sulfoximine (BSO), can be introduced to 
decrease the level of GSH in cancer cells when treating HCC. 
Also, both chemotherapeutic drugs used in the assay, 5FU and DOX, target 
fast growing cancer cells and interfere with DNA replication mechanism. 
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Since CL_x which has a slow proliferation rate, this property may render it 
less susceptible to the chemotherapeutic killing and thus shows a relatively 
higher drug resistance. 
The apoptotic pathway in which HBx is involved is not fully understood. 
Although the C-terminal two-thirds of HBx has been proven to be 
responsible for apoptosis and inhibiting cell growth in stably transfected cell 
lines in the TUNEL assay, the expression of the anti-apoptotic proteins, 
cIAP2 and Bcl-2 in different HBx transfected cell lines did not show a 
significant difference. The expression of these two anti-apoptotic proteins in 
transient transfection, on the other hand, was higher in CL—51 and CL_68 
which contained the C-terminal two-thirds of HBx. 
From the above results, it is possible to hypothesize that HBx may involve in 
apoptosis in different pathways of the early and the late infection in 
hepatocytes. In hepatitis B virus infection, the transactivation domain of 
HBx may at first produce some anti-apoptotic effects in hepatic cells to 
facilitate viral replication and then exerts pro-apoptotic effect after some time 
to spread the virus. The pathway which HBx is involved in late stage of 
transfection still needs further investigation. Also, the mechanism of HBx 
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Figure 5.4 Protein expression of anti-apoptotic proteins cIAP2 and Bcl-2 in different 
HBx transient transfected cell lines. Both proteins show a higher protein 
expression in CL一51 and CL_68. The bands are at 68kDa and 26kDa 
respectively for cIAP2 and Bcl-2. Lane 1 is CL, lane 2 is CL_pcDNA3.1, 
lane 3 is CL一50，lane 4 is CL一51，lane 5 is CL一68，lane 6 is CL_88，lane 7 is 
CL_106, lane 8 is CL_136 and lane 9 is CL_x. 
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Figure 5.5 Protein expression of anti-apoptotic proteins in different HBx stably 
transfected cell lines. (A) cIAP2, (B) Bcl-2. There is not much difference in 
the expression of those proteins. It shows a band at 68kDa and 26kDa 
respectively for cIAP2 and Bcl-2. Lane 1 is CL, lane 2 is CLjpcDNA3.1, 
lane 3 is CL 50, lane 4 is CL 51, lane 5 is CL 68，lane 6 is CL 88，lane 7 is 
CL_106, lane 8 is CL一 136 and lane 9 is CL_x. 
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Chapter 6: Concluding remarks and general discussion 
6.1 General discussions 
HCC is one of the most common cancer deaths worldwide and the mortality 
. r a n k s fourth among cancer. In Hong Kong, most of the cases of HCC are 
caused by HBV. HBx has been proven to be a critical protein in HBV-
related hepatocarcinogenesis and it is also important for viral replication and 
infection. The C-terminal of HBx has been proven to be essential for the 
transactivation function and involved in apoptosis. However, diverse reports 
have shown that HBx is both pro-apoptotic (Miao et al, 2005; Kim and 
Seong，2003; Kim et al, 2005; Terradillos et al, 2002; Kim et al, 1998; Doria 
et ah 1995; Benn et al, 1996; Su and Schneider, 1996; Shin et al, 1999; Yoo 
and Lee, 2004; Terradillos et al, 1998; Su and Schneider 1997; Kim et al, 
2005) and anti-apoptotic (Wang et al, 1995; Elmore et al, 1997; Chung et al, 
2003; Hsieh et a/, 2003; Lee and Rho, 2000; Feitelson et al, 1993; Gottlob et 
al 1998; Lee et al, 2001; Shih et al’ 2000; Diao et al, 2001; Cross et al, 1993; 
Benn and Schneider, 1994; Natoli et al, 1994) in liver cells. Also, HBx has 
been found to cause oxidative stress and alter antioxidant levels in liver cells 
(Waris et al, 2001; Chrobot et al, 2000; Yang et al, 2005; Bolukbas et ah 
2005). Drug resistance has been observed in various cancer cases and some 
believe that high antioxidant levels is the main cause (Estrela et al, 1995; 
Meister 1991; Arrick and Nathan, 1984; D'Andrea, 2005). 
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In our study, the role of HBx in affecting oxidative stress, antioxidant and 
apoptosis in liver cells was investigated. Results of our study show that HBx 
alters antioxidant levels and may play an important role in apoptosis of liver 
cells. 
Full length HBx and various mutants were stably transfected into Chang 
Liver (CL) cells successfully to produce CL_50, CL一51，CL一68，CL一88， 
CL一 106，CL一 136 and CL_x. The vector pcDNAS.l was also stably 
transfected into CL to produce CL_pcDNA3.1. The non-transfected CL and 
CL_pcDNA3.1 acted as the negative control. Both mRNA and protein 
expressions of the target genes were detected by RT-PCR and Western blot 
respectively. 
The limitation of stable transfection is that the level of the gene is not 
expressed as high as those in transient transfection. One of the major 
problems is that the antibodies for detecting the expression of HBx are not 
sensitive enough. It may make characterization of HBx expression in 
infected hepatocytes and liver tissues difficult. A report stated that in 11 
antibodies from different laboratories, only three of them reacted specifically 
to HBx (Su et al, 1998). In our research, we have tried four different anti-
HBx antibodies, rabbit polyconal anti-HBx antibody (BioVendor Laboratory 
Medicine, Inc., Modrice, Czech Republic), mouse monoclonal IgG IK anti-
HBx antibodies (MAB8419 and MAB8429) (Chemicon, Temecula, CA) and 
mouse monoclonal IgGi anti-HBx antibody (X36C) (Affinity Bioreagents 
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(ABR), Golden, CO). But only the one from ABR reacted positively with 
HBx. However, the bands were weak. The other problem was that the 
positions of integration of the genes in the host genome could not be 
controlled. To solve this problem, the clones obtained after selection with 
G418 should be sequenced and only the clones which have the desired 
integration positions are grown. 
The cells obtained from stable transfection were used to perform various 
assays. According to the antioxidant assay, the C-terminal of HBx was found 
to cause an elevation in GSH level. However, the total SOD activity was not 
significantly affected by HBx. The expression of MnSOD which was present 
mainly in the mitochondria is affected by HBx, the C-terminal of HBx may 
be responsible for it but no specific domain could be defined from the results 
of those experiments, A report suggested that an increase in the expression 
of MnSOD prevents apoptosis (Manna et al, 1998; Fujimura et al, 1999). 
We used the GSH assay kit to measure the concentration of GSH. The kit is 
originally designed to measure the concentration of both GSH and GSSG. 
But it was slightly modified in our study to just measure GSH concentration 
such that the antioxidant state of the cells was better assessed. 
For the role of HBx in apoptosis, the C-terminal of HBx, especially amino 
acid 88，was found to be responsible for inhibiting cell growth and promoting 
apoptosis. The pathway involved is not clearly known. In the transient 
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transfection, the protein expression level of two anti-apoptotic proteins, 
cIAP2 and Bcl-2, were found to be elevated. But in stable transfection, the 
expression of these two anti-apoptotic proteins did not have significant 
difference. Drug resistance was not observed generally in the cell lines 
transfected with HBx mutants, but the cell death rate was lower in cells 
transfected with full length HBx when compared with the negative control. 
The mechanism of HBx in hepatocarcinogenesis is still unclear. According 
to the results obtained, the C-terminal of HBx seems to be anti-apoptotic in 
transient transfection but it is pro-apoptotic in stable transfection. This may 
suggest that the C-terminal of HBx may initially exert an anti-apoptotic effect 
to facilitate viral replication in early infection, and later turn to be pro-
apoptotic to spread the virus in later stage of infection. 
The whole scenario of HBx in hepatocarcinogenesis can be hypothesized as 
follow ：~ 
in transient infection, the C-terminal of HBx exerted an anti-apoptotic effect 
to the liver cells by elevating the expression of both cIAP2 and Bcl-2. This 
suggests that in early HBV infection the cell growth mechanism in the 
infected hepatocytes and the neighboring cells may be switched on by HBx. 
However, in stable transfection, the C-terminal of HBx caused an increase in 
GSH concentration and apoptosis at the same time. Cells with a higher GSH 
level also showed a slower growth rate. This suggests that in later stage 
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HBV infection, the C-terminal of HBx causes oxidative stress in the infected 
hepatocytes and the antioxidant level increases to scavenge the free radical 
produced. At the same time, the same region of HBx causes a pro-apoptotic 
effect in the infected hepatocytes. Although the liver cells infected by HBV 
seem to be pro-apoptotic, the neighboring liver cells may undergo faster cell 
proliferation to compensate the dying cells and thus tumors may be formed. 
Also, the high level of GSH may cause drug resistance during chemotherapy 
which may render liver cancer difficult to be treated and lead to the poor 
survival rate. 
The C-terminal of HBx is preliminarily proven to be the functional domain to 
cause apoptosis, and it is also responsible for altering antioxidant levels in 
hepatocytes. Though the pathway is not fully know, these important findings 
help us to design better drugs which can target the specific domains of HBx. 
Eventually it may stop the replication of the virus. Most importantly, if the 
• • • . 
pathway of HBx involved in carcinogenesis is better known, more agents 
could be designed to inhibit the proteins involved in the cascade. This may 
be helpful in correcting the drug resistance seen in chemotherapy when 
treating HCC. 
6.2 Future work 
i) Since the pathway of HBx involved in apoptosis is not clear, the genes 
that activated or deactivated by HBx have not been identified in this 
study. So, microarray can be employed to preliminarily screen the genes 
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that are activated or deactivated in different HBx transfected cell lines 
such that the various pathways can be further investigated. 
ii) The subcellular localization of HBx, both the wild type and the mutant 
ones, should be defined. This can be done by using vector tagged with 
GFP in cloning the genes and the location of HBx can be observed 
directly using confocal microscope. This may allow us to better study the 
mechanism of HBx in regulating apoptosis in organelle such as 
mitochondria in which MnSOD is located. 
• . • . 
iii) Since the C-terminal of HBx especially amino acid 88 has been proven to 
be essential in the apoptotic pathway, drugs or blocking agents can be 
introduced to block the expression or function of the region. For example, 
short interfering RNA (siRNA) can be introduced to inhibit the 
expression of the target gene. On the other hand, if the pathway of HBx 
involved in apoptosis is better understood and the candidates it targets are 
known, blocking agents can be developed to block the interaction 
between HBx and its targets. 
iv) The assays in this project were all done based on the HBx transfected cell 
lines. The actual effects of HBx on live animals has not been assessed 
and they maybe different from those observed in cell lines. For better 
drug development or other therapies, the effect of HBx in oxidative stress 
and apoptosis should be further investigated in vivo. 
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6.3 Summary 
The C-terminal of HBx, especially amino acid 88, is essential in affecting 
GSH level and apoptosis. It is anti-apoptotic in transient transfection while it 
is pro-apoptotic in stable transfection. It may promote cell proliferation by 
elevating the expression of cIAP2 and Bcl-2 in transient transfection. But in 
stable transfection, the C-terminal of HBx may play a role in another 
pathway to promote apoptosis. Drug resistance is observed in cells 
transfected with full length HBx which can generate a high concentration of 
GSH. Indeed, the mechanism of HBx in oxidative stress, apoptosis and drug 
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